WO2010036937A1 - Topical formulations for treatment of neuropathy - Google Patents

Topical formulations for treatment of neuropathy Download PDF

Info

Publication number
WO2010036937A1
WO2010036937A1 PCT/US2009/058446 US2009058446W WO2010036937A1 WO 2010036937 A1 WO2010036937 A1 WO 2010036937A1 US 2009058446 W US2009058446 W US 2009058446W WO 2010036937 A1 WO2010036937 A1 WO 2010036937A1
Authority
WO
WIPO (PCT)
Prior art keywords
neuropathy
topical composition
pain
nmda
topical
Prior art date
Application number
PCT/US2009/058446
Other languages
French (fr)
Inventor
Richard Wolicki
Stanley Kim
Original Assignee
Taraxos Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taraxos Inc. filed Critical Taraxos Inc.
Priority to US13/120,894 priority Critical patent/US8629184B2/en
Priority to AU2009296457A priority patent/AU2009296457A1/en
Priority to CA2738468A priority patent/CA2738468A1/en
Priority to CN2009801471678A priority patent/CN102223791A/en
Priority to EP09816933A priority patent/EP2334176A4/en
Publication of WO2010036937A1 publication Critical patent/WO2010036937A1/en
Priority to US14/155,231 priority patent/US20140194514A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

  • the present invention relates to methods and compositions for the topical treatment of neuropathy. More particularly, the present invention relates to topical compositions including a combination of ingredients that provides a surprising degree of effective relief from the symptoms of neuropathy with minimal side effects and to methods for administering topical compositions to treat neuropathy. Preferred embodiments contemplate chemical, biological or physical means of reducing such side effects.
  • Peripheral neuropathy is a condition involving nerve-end damage anywhere in the body.
  • Peripheral neuropathy generally refers to a disorder that affects the peripheral nerves, most often manifested as one or a combination of motor, sensory, sensorimotor, or autonomic neural dysfunction.
  • the wide variety of morphologies exhibited by peripheral neuropathies can each be uniquely attributed to an equally wide variety of causes.
  • peripheral neuropathies can be genetically acquired, can result from a systemic disease, can manifest as a post-surgical complication, or can be induced by a toxic agent.
  • Some toxic agents that cause neurotoxicities are therapeutic drugs, antineoplastic agents, contaminants in foods or medicinals, and environmental and industrial pollutants. As much as 3% of the population is estimated to be affected, if not greater.
  • peripheral neuropathies include the following: HIV-associated neuropathy; nutritional deficiency-associated neuropathy; cranial nerve palsies; drug-induced neuropathy; industrial neuropathy; lymphomatous neuropathy; myelomatous neuropathy; multi-focal motor neuropathy; immune- mediated disorders, chronic idiopathic sensory neuropathy; carcinomatous neuropathy; acute pain autonomic neuropathy; alcoholic neuropathy; compressive neuropathy; vasculitic/ischaemic neuropathy; mono- and polyneuropathies.
  • peripheral neuropathy is a major complication of cancer treatment and is the main factor limiting the dosage of chemotherapeutic agents that can be administered to a patient (Macdonald, Neurologic Clinics 9:955-967 (1991)). This is true for the commonly administered agents cisplatin, paclitaxel and vincristine (Broun, et al., Am. J. Clin. Oncol. 16:18-21 (1993); Macdonald, Neurologic Clinics 9:955-967 (1991); Casey, et al., Brain 96:69-86 (1973)).
  • NMDA N-methyl-D-aspartate
  • NMDA receptor function is associated with an array of negative symptoms. They sometimes induce "psychotomimetic" side effects, symptoms resembling psychosis. Such side effects caused by NMDA receptor inhibitors can include hallucinations, paranoid delusions, confusion, difficulty concentrating, agitation, convulsions, alterations in mood, nightmares (Muir, KW; Lees KR (1995), and may exhibit personality changes and disorganized thinking. "Clinical experience with excitatory amino acid antagonist drugs". Stroke 26 (3): 503-513.) catatonia (Aarts, MM; Tymianski M (2003). "Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors".
  • ketamine transdermally in an organogel has shown some promise in the treatment of neuropathy. Because ketamine is an N-methyl-D-aspartate receptor antagonist it blocks a cascade of intracellular events that inhibit the hyper excitability of spinal cord neurons. Animal data show that certain spontaneous pains and allodynia have been treated successfully with Ketamine. Also, in humans, phantom limb pain has been treated with some success (Nadine & Bouhassira, Acta. Neurol. Scand 1999 (Supp 173): 12-24). Ketamine has been used experimentally to treat neuropathic pain by a variety of routes including the intravenous and subcutaneous.
  • Ketamine A topical form of low doses of Ketamine has shown some efficacy in treating painful neuropathy when other traditional medicines have failed. (Crowley et al., International Journal of Pharmaceutical Compounding 1998; 2:122-1273). [0009] Other compositions have been employed, including combinations of individual compounds.
  • SMP Sympathetically Mediated Pain
  • ketamine NMDA receptor antagonist
  • amitriptyline antagonist
  • guanethidine guanethidine
  • 2004/0204366 and 2004/0101582 attack the problem with a spectrum of analgesic compounds including combinations of ketamine, gabapentin and clonodine.
  • Other solutions have attempted to increase the absorption of the compounds, see, e.g., US Patent Publication. No. 2004/0076648. Each of these references is incorporated herein by reference.
  • PCT Publication WO 9807447 describes combinations of anti-epileptic compounds, including gabapentin, with NMDA receptor antagonists.
  • PCT Publications WO 9912537 and WO 0053225 describe combinations of NMDA antagonists and GABA analogs, including gabapentin and pregabalin.
  • PC Publication WO 0200434 describes the use of NMDA antagonists in the treatment of central neuropathic pain.
  • PCT Publication WO 05102390 describes alpha-2-delta ligands in combiation with NMDA antagonists as analgesics.
  • PCT Publication WO 03061656 describes a composition for treating disorders of the central nervous system comprising a GABA analog, such as gabapentin or pregabalin, with an NMDA receptor antagonist such as dextromethomorphan or d- methadone, optionally in combination with another pharmaceutically active substance.
  • a GABA analog such as gabapentin or pregabalin
  • an NMDA receptor antagonist such as dextromethomorphan or d- methadone
  • PC Publications WO 9912537 and WO 0053225 describe combinations of anti-epileptic compounds, including gabapentin and pregabalin, in combination with NMDA antagonists as analgesics.
  • PC Publication WO 03091241 describes NR2B antagonists for a number of indications, together with alpha-2-delta ligands, e.g. gabapentin and pregabalin.
  • compositions described herein can provide for the treatment of peripheral neuropathy, and can include a therapeutically effective amount of at least one NMDA antagonist and one additional active compound in a pharmaceutically acceptable diluent or carrier suitable for topical or transdermal use.
  • the NMDA antagonist is provided in relatively high concentrations, such as greater than 15% by weight.
  • NMDA antagonists may include, but are not limited to, PCP, nitrous oxide, ketamine, MK-801 , methadone, dextropropoxyphene, and ketobemidone.
  • methods described herein are directed to treating peripheral neuropathy, comprising the step of transdermal or topical administration of an effective amount of a pharmaceutical composition as described herein to the affected area of a subject in need of such treatment.
  • Other drugs or ingredients may be added as needed to increase the analgesic effect or minimize the side effects.
  • the peripheral neuropathy is a diabetic neuropathy. It will be clearly understood that the diabetic neuropathy may be associated with Type 1 (insulin-dependent) diabetes, Type 2 (non-insulin-dependent) diabetes, or both.
  • the neuropathy is a non-diabetic neuropathy.
  • a non-diabetic neuropathy may be genetically acquired, such as Charcot-Marie-Tooth syndrome.
  • the peripheral neuropathy can result from a systemic or infectious disease such as HIV, or an infectious disease condition such as AIDS.
  • the peripheral neuropathy manifests as a post surgical complication.
  • the peripheral neuropathy is induced by a toxic agent.
  • the peripheral neuropathy can be caused by a chemotherapeutic agent such as paclitaxel (or other taxane derivative), vincristine, cisplatin, an agent used for the treatment of infectious diseases such as streptomycin, didanosine or zalcitabine, or any other chemically toxic agent.
  • chemotherapeutic agent such as paclitaxel (or other taxane derivative), vincristine, cisplatin
  • infectious diseases such as streptomycin, didanosine or zalcitabine
  • Infectious disease conditions such as post-polio syndrome or AlDS- associated neuropathy are specifically contemplated.
  • peripheral neuropathies include the following: HIV associated neuropathy; B12-deficiency associated neuropathy; cranial nerve palsies; drug-induced neuropathy; industrial neuropathy; lymphomatous neuropathy; myelomatous neuropathy; multi-focal motor neuropathy; chronic idiopathic sensory neuropathy; carcinomatous neuropathy; acute pan autonomic neuropathy; alcoholic neuropathy; compressive neuropathy; vasculitic/ischaemic neuropathy; mono- and poly-neuropathies.
  • the neuropathy is due to low back pain, Guillain- Barre Syndrome, sciatica, or other chronic pain.
  • Further embodiments include methods for treating a subject suffering from peripheral neuropathy, the methods comprising topically administering an effective amount of the composition consisting essentially of ketamine and gabapentin formulated in a pharmaceutically acceptable topical carrier.
  • the methods comprise topically administering an effective amount of a composition comprising a NMDA antagonist formulated in a pharmaceutically acceptable carrier for topical treatment.
  • compositions described herein can be administered in therapeutically effective amounts.
  • a therapeutically effective amount means the amount required to at least partly to attain the desired effect, e.g., to effectively alleviate or prevent the symptoms of the peripheral neuropathy or pain, to mitigate the side effects of certain compounds such as neurotoxicity or psychosis or drowsiness, to effectuate or potentiate the activity of the invention composition, or combinations thereof.
  • the pharmaceutical compositions described herein can be used for the treatment of peripheral neuropathy.
  • These compositions can include therapeutically effective amounts of at least one NMDA (receptor) antagonist and one additional active ingredient, such as gabapentin or clonidine which limits or mitigates the side effects of the NMDA (receptor) antagonist.
  • the composition is formulated in a pharmaceutically acceptable diluent or carrier suitable for transdermal or topical use.
  • NMDA (receptor) antagonist Prior compositions used a plurality additional ingredients to counter the side effects of NMDA (receptor) antagonists.
  • prior compositions included ketamine, clonidine and gabapentin (See U.S. Publication 2004-0101582A1).
  • the composition consists essentially of ketamine and gabapentin to treat neuropathy when the composition is administered topically in a physiologically acceptable vehicle. In one embodiment, the composition consists essentially of at least about 15% or 20% or more ketamine and at least about 3% gabapentin.
  • the treatment of neuropathy refers to an anti-neuropathic response or a pain-reducing response elicited through the synergistic effect of the two compositions within each formulation as described herein, in which the combined effect of the two agents effectively mitigates, relieves, alleviates, reduces or removes the symptoms of peripheral neuropathy, provides a beneficial effect to the subject; and/or effectively mitigates or reduces the side effects associated with the NMDA-receptor antagonist.
  • the compositions described herein may provide one or more of the following beneficial effects to a patient when topically applied in effective amounts: relief of pain, burning, tingling, electrical sensations and/or hyperalgesia.
  • NMDA-receptor antagonist or “NMDA antagonist” encompasses compounds that may block or inhibit the action of the N-methyl d- aspartate (NMDA) receptor.
  • the receptor can be deactivated by inhibitors that can cause the NMDAR (NMDA receptor) to close by binding to allosteric sites, e.g., 1) Competitive antagonists, which bind to and block the binding site of the neurotransmitter glutamate; 2) glycine antagonists, which bind to and block the glycine site; 3) noncompetitive antagonists, which inhibit NMDARs by binding to allosteric sites; and 4) uncompetitive antagonists, which block the ion channel by binding to a site within it; or that block the NMDA receptor by another mechanism.
  • NMDA-receptor antagonists include, but are not limited to: Amantadine -"Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on
  • Dizocilpine (MK-801) - Fix AS, Horn JW, Wightman KA, et al (1993). "Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex". Exp. Neurol. 123 (2): 204-15. Aptiganel (Cerestat, CNS-1102) - binds the Mg2+ binding site within the channel of the NMDA receptor.
  • NMDA N-methyl-D-aspartate
  • AP7 (2-amino-7-phosphonoheptanoic acid) - van den Bos R, Charria Ortiz G, Cools A (1992).
  • D-2-amino-7-phosphonoheptanoic acid (AP-7) into the nucleus accumbens of rats enhance switching between cue- directed behaviours in a swimming test procedure.
  • NMDA-receptor antagonists include, but are not limited to, eliprodil; iamotrigine; flupirtine; celfotel; levemopamil; pyroloquinoline quinone; cis-4- (phosphonomethyl)-2-piperdine carboxylic acid; l-(4-hydroxy-phenyl)-2-(4-phenylsulfanyl- piperidin-l-yl)-pro pan- 1 -one; 2-[4-(4-fluoro-benzoyl)-piperidin-l-yl]-l-naphthalen-2-yl-et hanone (E 2001); 3-(l,l-dimethyl-heptyl)-9-hydroxyrnethyl-6,6-dimethyl-6a,7,8 ,10a- tetrahydro-6H-benzo[c]chromen-l-ol (HU-21 1); l- ⁇ 4-[l -(4-[l
  • references that disclose other NMDA-receptor antagonists as well as assays for identifying NMDA-receptor antagonists include Jia-He Li, et al., 38 J. Med. Chem. 1955 (1995); Bigge 45 Biochem. Pharmacol. 1547 (1993); Steinberg et al, 133 Neurosci. Lett. 225 (1991); Meldrum et al., 1 1 Trends Pharmacol. Sci., 379 (1990); Willetts et al., 1 1 Trends Pharmacol. Sci. 423 (1990); Faden et al., 13 Trends Pharmacol. Sci. 29 (1992); Rogawski 14 Trends Pharmacol. Sci. 325 (1993); Albers et al, 15 Clinical Neuropharm.
  • the NMDA antagonist may be an NMDA antagonist that would not be considered for general clinical use by itself, particularly in higher amounts or usage, due to its side effects.
  • the NMDA antagonist is a non-competitive channel blocker such as PCP, nitrous oxide, ketamine, MK-801, dextromethorphan, amantadine, dextromethorphan, ibogaine, ketamine, norketamine, memantin, riluzole, tiletamine, dextrorphan, and phencyclidine, and the like.
  • NMDA- receptor antagonists that are existing pharmaceuticals or nutraceuticals (e.g., have undergone one or more regulatory trials in humans or animals (e.g., FDA based Phase I, Phase II and/or Phase III trials) are also within the scope of the invention.
  • the NMDA- receptor antagonist described herein is a non-competitive NMDA-receptor antagonist, more preferably, ketamine or norketamine, even more preferably, ketamine hydrochloride.
  • Ketamine is an N-methyl-D-aspartate (NMDA) calcium channel antagonist that can be admixed in the compositions described herein in concentrations ranging from 10-50%, preferably 10 to 40%, and most preferably from 15% to 20% or to 25% - 30%.
  • the topical formulation has about 15% ketamine.
  • the topical formulation has about 20% ketamine.
  • the topical formulation has about 25% ketamine.
  • the amount of NMDA-receptor antagonist in the compositions of the invention is within the range of from about 0.1 percent to about 100 percent of the total weight of the composition, more preferably, of from about 3 percent to about 50 percent of the total weight of the composition. More preferably, the range is from about 10 percent to about 40 percent of the total weight, and includes the ranges, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40.
  • the amount of ketamine in the invention composition is within the range of from about 5% to about 40%, more preferably from about 10% to about 40, more preferably from about 15% to about 30%, even more preferably from about 20% to about 25%, or alternatively, greater than 10% or 15%.
  • NMDA antagonist employed in the present invention would likely, prior to applicant's disclosure, be considered too high for clinical application, e.g., too high for one time use or, alternatively, too high for repeated use particularly on a large population of patients.
  • compositions described herein provide an effective antineuropathic response through two compounds that in combination provide effective analgesia with a low or reduced side effect profile.
  • the formulations in combination would provide a lower side effect profile than the individual components taken independently, particularly in higher concentrations or dosages.
  • Other properties which may be considered is the effective half life of the composition, the ability to cross or not cross the blood brain barrier, the ability of the compound to remain local in proximity to the topical administration, increase or decrease in blood pressure, psychomimetic symptoms, drowsiness, and the like.
  • Those of skill in the art will recognize compounds and side effect profiles of compounds suitable in the present invention.
  • side effects encompasses unwanted and adverse effects of a therapy (e.g., a prophylactic or therapeutic agent).
  • a therapy e.g., a prophylactic or therapeutic agent
  • An adverse effect from a therapy might be harmful or uncomfortable or risky.
  • Side effects include, but are not limited to fever, chills, lethargy, gastrointestinal toxicities (including gastric and intestinal ulcerations and erosions), nausea, vomiting, neurotoxicities, psychotomimetic effects, nephrotoxicities, renal toxicities (including such conditions as papillary necrosis and chronic interstitial nephritis), hepatic toxicities (including elevated serum liver enzyme levels), myelotoxicities (including leukopenia, myelosuppression, thrombocytopenia and anemia), dry mouth, metallic taste, prolongation of gestation, weakness, somnolence, pain (including muscle pain , bone pain and headache), hair loss, asthenia, dizziness, extra pyramidal symptoms, akathisia, cardiovascular disturbances and sexual dysfunction.
  • NMDA receptor antagonists that can used as the second active compound within the formulations described herein in order to reduce unwanted side effects.
  • Centrally-acting alpha-2 agonists such as clonidine and guanfacine are thought to most specifically target the etiology of NMDA neurotoxicity (see, e.g., US Pat. App. Nos. 20050148673, 20050222270, 20020068754 and 20020016319, and PCT App. No. WO/2001/089448A2).
  • NMDA antagonist neurotoxicity drugs acting on various neurotransmitter systems known to inhibit NMDA antagonist neurotoxicity include: anticonvulsants or antiepileptics, anticholinergics (see, e.g., US Pat. No. 5034400, 5616580, 5605911, 5767130 and 5902815), tri-cyclo-alkyl-amine (TCAA) structure (US Pat. No. 20020177592) diazepam, barbiturates [Olney J, Labruyere J, Wang G, Wozniak D, Price M, Sesma M (1991). "NMDA antagonist neurotoxicity: mechanism and prevention". Science 254 (5037): 1515-8; US Pat. No.
  • the anticonvulsants also called antiepileptic drugs (abbreviated "AEDs"
  • AEDs antiepileptic drugs
  • the goal of an anticonvulsant is to suppress the rapid and excessive firing of neurons that start a seizure. Failing this, a good anticonvulsant would prevent the spread of the seizure within the brain and offer protection against possible excitotoxic effects that may result in brain damage.
  • Certain anticonvulsants prevents Olney vacuole formation neurotoxicity of MK-801, an NMDA antagonist, when injected into female rats, see Farber, N B, et al. "Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity.” MoI Psychiatry 2002; 7(7): 726-733.
  • Examples of useful anticonvulsants include, but are not limited to, acetylpheneturide, albutoin, aloxidone, aminoglutethimide, 4-amino-3-hydroxybutyric acid, atrolactamide, beclamide, buramate, calcium bromide, carbamazepine, cinromide, clomethiazole, clobazam, clonazepam, decimemide, diethadione, dimethadione, doxenitroin, eterobarb, ethadione, ethosuximide, ethotoin, felbamate, fluoresone, fosphenytoin, gabapentin, 5-hydroxytryptophan, lamotrigine, levetiracetam, magnesium bromide, magnesium sulfate, mephenyloin, mephobarbital, metharbital, methetoin, methsuximide, 5- methyl-5-(3-phenanthryl)-
  • Gabapentin is a glutamate antagonist at the NMDA and AMPA (sodium channel) receptor sites.
  • This agent can be admixed in strengths ranging from 1 to 30 percent, preferably strengths less than 15%, more preferably in strengths 10% or less, including in 1 , 2, 3, 4, 5, 6, 7 and 8%.
  • the formulation has 3% - 6% gabapentin, but it can be included in amounts of 1%, 2%, 4%, 5%, 7%, 8%, 9%, or therebetween. More dosing flexibility is allowed transdermally because of its relatively low systemic concentration. See Bakonja M, Baydoun A, Edwards K R, et al.
  • compositions described herein can be used to potentiate the action of NMDA -receptor antagonists such as ketamine.
  • analgesics can be any known in the art, including, but not limited to NMDA ligands, AMPA ligands, non-NMDA or AMPA ligands, TNF-I ⁇ ligand, GABA ligand, ⁇ -2 ligands, and the like.
  • Such analgesics can include clonidine, capsaicin, lidocaine, bupivacaine, mepivacaine, ropivacaine, tetracaine, etidocaine, chloroprocaine, prilocaine, procaine, benzocaine, dibucaine, dyclonine hydrochloride, pramoxine hydrochloride, benzocaine, lacosamide and proparacaine. It is preferable that the topical formulation have as little of a side effect profile for a large population of patients.
  • compositions described herein can further comprise additional ingredients that can increase the analgesic effectiveness of the combination of invention composition.
  • additional ingredients can facilitate the effect of this combination or compounds by increasing absorption and/or penetration, provide for a more comprehensive pain management regimen, decrease the side effect profile of the base composition, or the like.
  • magnesium ions e.g., from magnesium oxide or other magnesium preparations
  • antagonize ionic calcium in the nervous system enhancing the effect of the present invention.
  • compositions co-administration with a magnesium salt may increase the pain-relieving efficacy of this treatment in at least some cases.
  • salt includes any compound or complex that releases substantial quantities of free magnesium ions (Mg ++) when dissolved in an aqueous solution.
  • Nerve impulse conduction is blocked by a decrease in nerve cell membrane permeability to sodium ions, possibly by competing with calcium-binding sites that control sodium permeability. This change in permeability results in decreased depolarization and an increased excitability threshold that ultimately prevents the nerve action potential from forming.
  • Ionic calcium is antagonized by magnesium ions in the nervous system. Because of this, dietary supplements of magnesium oxide and other magnesium preparations may increase or enhance the effects of calcium channel blockade.
  • Mg++ ions can effect muscle relaxation through direct action on the cell membrane.
  • Mg++ ions close certain types of calcium channels, which conduct a positively charged calcium ion into the neuron. With an excess of magnesium, more channels will be blocked and the nerve will have less activity.
  • compositions described herein can further comprise non- physiologically active ingredients or components usually admixed in such topical preparations (besides an NMDA antagonist and a second active ingredient, such as an anticonvulsant).
  • the compositions may also include additional ingredients such as other carriers, moisturizers, oils, fats, waxes, surfactants, thickening agents, antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives, perfumes, dyestuffs, lower alkanols, humectants, emollients, dispersants, sunscreens such as radiation blocking compounds or particularly UV-blockers, antibacterials, antifungals, disinfectants, vitamins, antibiotics, or other anti-acne agents, as well as other suitable materials that do not have a significant adverse effect on the activity of the topical composition.
  • Additional inactive ingredients for inclusion in the carrier may be sodium acid phosphate moisturizer, witch hazel extract carrier, glycerin humectant, apricot kernel oil emollient, corn oil dispersant, and the like which are further detailed below.
  • additional inactive ingredients which can be admixed in the compositions described herein.
  • compositions described herein can optionally contain other ingredients.
  • triethanolamine can be added as a crosslinking agent.
  • a preservative such as betahydoxytoluene can also be added.
  • Other irritation reducing agents can be added too.
  • irritation reducing agents can include, but are not limited to, glycerol.
  • semi-solid testosterone formulations have been prepared with propylene glycol and/or butylene glycol as the glycol component, ethyl alcohol and/or isopropyl alcohol as the alcohol component.
  • Preservatives, a cross-linking agent, and additional irritation reducing agents can be included in formulations prepared in accordance with the methods described.
  • compositions and methods of the invention are effective to induce local anaelgesia and to treat neuropathic pain.
  • neuropathic pain refers to neuropathic-pain syndromes, that is, pain due to lesions or dysfunction in the nervous system.
  • compositions and methods of the invention can be used to treat or prevent pain related to or induced by the following diseases, trauma, or conditions: general neuropathic conditions, such as peripheral neuropathy, phantom limb pain, reflex- sympathetic dystrophy, causalgia, syringomyelia, and painful scar; specific neuralgias at any location of the body; back pain; diabetic neuropathy; alcoholic neuropathy; metabolic neuropathy; inflammatory neuropathy; chemotherapy-induced neuropathy, herpetic neuralgias; traumatic odontalgia; endodontic odontalgia; thoracic-outlet syndrome; cervical, thoracic, or lumbar radiculopathies with nerve compression; cancer with nerve invasion; traumatic-avulsion injuries; mastectomy, thoracotomy pain; spinal-cord-injury; stroke; abdominal-cutaneous nerve entrapments; tumors of neural tissues; arachnoiditis; stump pain; fibromyalgia; regional sprains or strains; my
  • active means a compound or ingredient that exerts a physiological affect.
  • compounds that reduce, eliminate, or alleviate the side effects of an NMDA-receptor antagonist would be active compounds.
  • Inactive compounds or ingredients are those that do not exert a physiological effect on a patient or subject or do not reduce, eliminate, or alleviate side effects of NMDA-receptor antagonists.
  • Topical application of the composition may be useful for relieving pain, inflammation and irritation associated with skin diseases and disorders, such as psoriasis, pruritus, and lesions. Painful lesions develop, for example, from viral infections, skin cancers and genetic disorders. Topical application of the composition provides relief from pain associated with wounds, insect and animal bites, abrasions and burns, including those resulting from over-exposure to the sun, chemicals, radiation or chemotherapeutic agents. Acute post-operative or surgical pain can be reduced or even prevented, as can pain associated with chronic disorders, such as arthritis.
  • skin diseases and disorders such as psoriasis, pruritus, and lesions. Painful lesions develop, for example, from viral infections, skin cancers and genetic disorders.
  • Topical application of the composition provides relief from pain associated with wounds, insect and animal bites, abrasions and burns, including those resulting from over-exposure to the sun, chemicals, radiation or chemotherapeutic agents. Acute post-operative or surgical pain can
  • the methods described herein can provide a treatment of applying the compositions described herein to an affected area of a subject with diabetic polyneuropathy.
  • the methods described herein can include treating peripheral neuropathy, comprising the step of topical administration of a pharmaceutical composition of ketamine in a topical vehicle to the affected area of a subject in need of such treatment.
  • the methods and compositions described herein can be effective for neuropathies, particularly peripheral neuropathies, associated with diseases such as: uremia; childhood cholestatic liver disease; chronic respiratory insufficiency; alcoholic polyneuropathy; multiple organ failure; sepsis; hypoalbuminemia; eosinophilia-myalgia syndrome; hepatitis; porphyria; hypoglycemia; vitamin or nutritional deficiency (e.g., B-12 deficiency); chronic liver disease; primary biliary cirrhosis; hyperlipidemia; leprosy; Lyme disease; herpes zoster; Guillain-Barre syndrome; chronic inflammatory demyelinating polyradiculoneuropathy; sensory perineuritis; HIV or acquired immunodeficiency syndrome (AIDS) — associated neuropathy; Sjogren's syndrome; primary vasculitis (such as polyarteritis nodosa); allergic granulomatous angiitis; hypersensitivity
  • Genetically acquired neuropathies suitable for treatment by the methods and compositions described herein include, without limitation: peroneal muscular atrophy (Charcot-Marie-Tooth Disease) hereditary amyloid neuropathies, hereditary sensory neuropathy (type I and type II), porphyric neuropathy, hereditary liability to pressure palsy, Fabry's Disease, adrenomyeloneuropathy, Riley-Day Syndrome, Dejerine-Sottas neuropathy (hereditary motor-sensory neuropathy-Ill), Refsum's disease, ataxia-telangiectasia, hereditary tyrosinemia, anaphalipoproteinemia, abetalipoproteinemia, giant axonal neuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy, and Friedrich's ataxia.
  • peroneal muscular atrophy (Charcot-Marie-Tooth Disease) hereditary amyloid neuropathies, hereditary sensory neuropathy (type I and type II), porphy
  • compositions described herein are directed to treatment of neuropathic pain, especially pain caused by nerve injury or sympathetically mediated pain.
  • Sympathetically mediated pain is a type of pain in which over activity of the sympathetic nervous system plays a crucial role. It includes the syndromes of reflex sympathetic dystrophy (RSD), causalgia, neuropathic pain secondary to nerve injury, and pain from neuromas. It encompasses all neurogenic pain that is not central and is related to a nerve injury regardless of the cause.
  • Neuropathic pain syndromes include, without limitation (other than the neuropathies described herein), allodynia, various neuralgias such as post herpetic neuralgia and trigeminal neuralgia, phantom limb pain, hyperpathia, hyperesthesia, hyperalgesia, dyesthesia, paresthesia, anesthesia delorosa, deafferatation pain, and complex regional pain syndromes (CRPS), such as reflex sympathetic dystrophy (RSD) and causalgia.
  • RSD reflex sympathetic dystrophy
  • Specific examples include low back pain, sciatica, Guillain-Barre Syndrome, post-surgical traumatic neuropathy, and diabetic peripheral polyneuropathy.
  • compositions described herein can assume any of a variety of dosage forms, including solutions, suspensions, ointments, and solid inserts. Examples are creams, lotions, gels, ointments, suppositories, sprays, foams, liniments, aerosols, buccal and sublingual tablets, various passive and active topical devices for absorption through the skin and mucous membranes, including transdermal applications, and the like.
  • Typical pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or vegetable oils, and water-soluble ophthalmologically acceptable non-toxic polymers, for example, cellulose derivatives such as methylcellulose.
  • a typical cream or ointment-type carrier for topical application that can be used according to the methods and compositions described herein include a mixture of water, glycerin, propylene glycol, and methylparaben.
  • Topical carriers may also include other conventional emulsifiers and emollients including alginates, glyceryl stearate, PEG-100 stearate, cetyl alcohol, propylparaben, butylparaben, sorbitols, polyethoxylated anhydrosorbitol monostearate (TWEEN), white petrolatum (VASELINE), triethanolamine, Emu oil, aloe vera extract, lanolin, cocoa butter, and the like. Suitable topical carriers are well known to the skilled artisan.
  • Lipoderm® (Professional Compounding Centers of America, Houston, Tex.) is admixed in the compositions described herein.
  • Alternative ointment bases are known to persons skilled in the art such as Transcutol-P (ethoxydiglycol, commercially available, for example, from Gattefosse, Westwood, NJ).
  • Sufficient Lipoderm® base is admixed to act as a carrier for the active ingredients of the composition.
  • the Lipoderm® base will make up more than about 50% of the total composition and more preferably about 70% of the composition is the Lipoderm® base.
  • the Lipoderm® base functions as a carrier and enhances penetration through the skin. It is also hypoallergenic and is aesthetically pleasing.
  • matrix refers to an active permeant or drug dissolved or suspended in a biocompatible polymeric phase, preferably a pressure sensitive adhesive, that can also contain other ingredients or in which the enhancer is also dissolved or suspended.
  • a matrix system usually and preferably comprises an adhesive layer having an impermeable film backing laminated onto the distal surface thereof and, before transdermal application, a release liner on the proximal surface of the adhesive. The film backing protects the polymeric phase of the matrix patch and prevents release of the drug and/or enhancer to the environment.
  • the release liner functions similarly to the impermeable backing, but is removed from the matrix patch prior to application of the patch to an application situs.
  • Matrix patches are known in the art of transdermal drug delivery to routinely contain such backing and release liner components, and matrix patches according to the compositions described herein should be considered to comprise such backing and release liner or their functional equivalents.
  • U.S. Pat. No. 5,122,383 (incorporated herein by reference) describes such backing and release liner.
  • a matrix system therefore relates to a unit dosage form of a drug composition in a polymeric carrier, also containing the enhancer and other components that are formulated for maintaining the drug composition in the polymeric layer in a drug transferring relationship with the derma, i.e. the skin or mucosa.
  • a matrix patch is distinguished from a "liquid reservoir patch," wherein an active permeant or drug is dissolved in a gelled liquid contained in an occlusive device having an impermeable back surface and an opposite surface configured appropriately with a permeable membrane and adhesive for transdermal application, e.g., U.S. Pat. No. 4,983,395, incorporated herein by reference in its entirety.
  • a typical transdermal formulation comprises a conventional aqueous or non-aqueous vehicle, for example, a cream, ointment lotion or paste or in the form of a medicated plaster, patch or membrane.
  • the term "effective amount" of a drug or permeant relates to a nontoxic but sufficient amount of a compound to provide the desired local or systemic effect without adverse side effects.
  • An "effective amount” of permeation enhancer as used herein relates to an amount selected so as to provide the desired increase in membrane permeability and, correspondingly, the desired depth of penetration, rate of administration, and amount of drug.
  • “application situs” relates to a site suitable for topical application with or without the means of a device, patch, or dressing, e.g. the spinal column, behind the ear, on the arm, back, chest, abdomen, leg, top of foot, etc.
  • the cream can be applied to the site of pain or the spine dermatome(s) of the pain site, e.g., L2-S2 for any leg, knee, or foot neuropathy.
  • transdermal delivery also includes numerous different systems for the transdermal delivery of active agents known in the art.
  • Transdermal delivery systems include but are not limited to passive devices such as drug-in-adhesive transdermal patches and "active" transdermal technologies such as iontophoresis, electroporation, sonophoresis, magnetophoresis, microneedle devices and those devices that use thermal energy to make the skin more permeable.
  • Transdermal drug delivery devices are available from the 3M Drug Delivery Systems Division (St. Paul, Minn., USA), Noven Pharmaceuticals, Inc. (Miami, FIa., USA), ImaRx (Tucson, Ariz., USA), Elan Corporation (Dublin, Ireland), Novosis AG (Miesbach, Germany), Ultrasonic Technologies (St. Albans, Vt., USA), Antares Pharma (Exton, Pa., USA), Altea Therapeutics (Tucker, Ga., USA), Iomed, Inc. (Salt Lake City, Utah, USA), MacroChem Corp (Lexington, Mass., USA), Sontra Medical Corporation (Franklin, Mass., USA), Vyteris, Inc.
  • compositions of the invention can further comprise inactive compounds, such as penetration enhancers.
  • inactive compounds such as penetration enhancers.
  • the amount of penetration enhancer is preferably from about 1% to about 10% by weight of the total composition weight, more preferably from about 2% to about 5% by weight.
  • Penetration enhancers can be included in some embodiments to optimize transfer of the NMDA-receptor antagonist through the stratum comeum and into the dermis/dermatome to provide a local effect.
  • Percutaneous Penetration Enhancers Eric W. Smith & Howard I. Maibach eds. 1995
  • the penetration enhancer should be pharmacologically inert, non-toxic, and non-allergenic, have rapid and reversible onset of action, and be compatible with the compositions of the invention.
  • penetration enhancers include, but are not limited to, transcutol P, ethyl alcohol, isopropyl alcohol, lauryl alcohol, salicylic acid, octolyphenylpolyethylene glycol, polyethylene glycol 400, propylene glycol, N- decylmethylsulfoxide, DMSO and the azacyclo compounds, as disclosed in U.S. Pat. Nos. 4,755,535; 4,801,586; 4,808,414; and 4,920,101 , all of which patents are hereby expressly incorporated herein by reference.
  • the penetration enhancer is transcutol P.
  • compositions of the invention are prepared according to standard methods, well known in the art, for preparing emulsions for topical administration.
  • methods for preparing emulsions for topical administration.
  • Example preparations are recited in the Example section below.
  • compositions described herein can be made by cold compounding. This is significant since one or more of the compounds admixed in the topical compositions described herein may be sensitive to heat or other types of energy. Thus the activity of the composition may be detrimentally affected as a result of the formulation of the compositions in other manners.
  • the ingredients of this topical composition can be merely mixed together, without heating and using a sufficient amount of the carrier to provide a substantially homogeneous cream or gel. It is generally preferred to dissolve, disperse or suspend one or more of the ingredients prior to cold compounding in order to ensure substantially homogeneous distribution of the active ingredients in the composition.
  • the components can be separated into those that are water- soluble and those that are oil-soluble.
  • the water-soluble components can be mixed together in one vessel to form a solution and the oil-soluble components can be mixed together in a separate vessel and heated (e.g., 70° C. to 80° C.) to form a solution.
  • the two solutions can then be mixed and the mixture allowed to cool.
  • This method requires nothing more than two beakers and a heating apparatus. Homogenation is achieved using a high-shear rate blender or other suitable apparatus.
  • the appropriate droplet size is achieved by standard adjustment of the shear rate during high-speed mixing followed by droplet size analysis as described in Gennaro, A.
  • compositions are then packaged and stored according to well-known methods. For example, see the packaging procedures described in 1 Remington: The Science and Practice of Pharmacy 390-391 (Alfonso R. Gennaro ed., 19th ed. 1995 - updated in Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams & Wilkins (2006)), hereby incorporated herein by reference.
  • the compositions of the invention can be sterilized according to well-known methods, for example, the methods described in 2 Remington: The Science and Practice of Pharmacy 1463-1486 (Alfonso R. Gennaro ed., 19th ed. 1995 - updated in Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 21 st edition, Lippincott, Williams & Wilkins (2006)), hereby incorporated herein by reference.
  • composition is through “topical administration.”
  • topical administration or “topical application” refers to directly layering or spreading upon epidermal tissue, especially outer skin or membrane, including but not limited to the skin or membrane of cutaneous, mucosal or oral, vaginal, rectal, ocular, or nasal surfaces or cavities.
  • the composition is topically administered to a subject in an amount and duration sufficient to prevent or relieve pain associated with any cause, including, but not limited to, neuropathic inflammation, and acute and chronic peripheral neuropathy.
  • patches suitable for use with compositions of the invention include (1) the matrix-type patch; (2) the reservoir-type patch; (3) the multi-laminate drug-inadhesive type patch; (4) the monolithic drug-in-adhesive type patch; and (5) hydrogel patch; see generally Ghosh, T. K.; Pfister, W. R.; Yum, S. I. Transdermal and Topical Drug Delivery Systems , Interpharm Press, Inc. p. 249-297, hereby expressly incorporated herein by reference). These patches are well known in the art and available commercially.
  • the active ingredient e.g., NMDA antagonist, optionally combined with anticonvulsants or other compounds which may reduce the side effects of NMDA antagonists, analgesics, and the like
  • the active ingredient will comprise from about 0.5 percent to about 40 percent by weight of the patch, preferably from about 10 percent to about 30 percent, more preferably from about 15 percent to about 25 percent, and most preferably from about 18 percent to about 22 percent by weight of the patch.
  • the dosage to achieve pain relief is determined by the active surface area of the medicated portion of the patch in direct contact with the skin.
  • Several dosage strengths are advantageous depending upon the severity of the wound.
  • a physician can begin dosing with a low or intermediate strength patch and then, depending upon the effectiveness, adjust the dosage up or down by prescribing a patch of higher or lower active concentration or a patch of larger or smaller surface area, or, in some cases, multiple patches.
  • the composition of the invention will comprise from about 0.5 percent to about 20 percent by weight of the patch, preferably from about 5 percent to about 25 percent by weight of the patch.
  • compositions of the invention will comprise from about 0.5 percent to about 20 percent by weight of the patch.
  • compositions of the invention will comprise from about 0.5 percent to about 10 percent by weight of the patch.
  • Fresh patches may be administered multiple times per day, but, preferably, a fresh patch is administered about every 18 to about every 48 hours, more preferably daily.
  • All reagents used in the Examples below are also commercially available from international standard sources, for example from, Spectrum Laboratory Products, Inc. Gardena, Calif.; Lab Express International Inc. NJ; AK Chemical Tech and Shandong Zhonggong Chemical Co.Ltd., Shanghai Gupeng International Trading Co., Ltd., Beijing Medicine Chemical Co., Ltd., in China; Greenspharma, Maps Pharmaceuticals of India. Additional searches online will result in additional sources for such compounds.
  • One source for gabapentin is Spectrum Laboratory Products, Inc. and ketamine hydrochloride is from Medisca, Inc., Plattsburg, N.Y.
  • Transdermal bases differ from topical bases, e.g., petrolatum or cold cream, in that they facilitate the penetration of the active chemicals through all dermal layers. This subcutaneous entry, in turn, allows the active chemicals to penetrate the nerve fibers themselves.
  • the PCCA transdermal base Lipoderm is preferred due to its proven penetration superiority over PLO (pluronic-lecithin-organogel).
  • Formulation [0079] Ketamine HCl and Gabapentin powders can be accurately weighed by any FDA-approved scale. Water is measured using any approved cylindrical graduate. The powders are first filtered through a fine-mesh screen into a glass mortar then dissolved by the addition of water.
  • EMP electronic mortar and pestle
  • the Lipoderm (or similar) transdermal base is then geometrically levigated into the dissolved powders.
  • Krisgel (or similar) is then stirred into the mixture until evenly distributed.
  • the mixture is then milled in a three-roller ointment mill (Exakt 50 or similar) and then dispensed in an appropriate ointment jar.
  • Gabapentin can also be in weights of 3%.
  • Gabapentin can also be in weights of 3% with an increase in the amount of the Lipoderm Base.
  • the anticipated dose of Neurocreme is up to 2-5 grams per day. This dose translates to a topical administration of 400 mg of ketamine hydrochloride and 60 mg of gabapentine.
  • the active ingredients of the compositions described herein are composed of two chemicals within a transdermal base.
  • the chemicals are (1) ketamine hydrochloride, an N-methyl-D-aspartate (NMDA) calcium channel antagonist in concentrations of 15% or 20% when combined with gabapentin.
  • Gabapentin a glutamate antagonist at the NMDA and AMPA (sodium channel) receptor sites. Its concentration is typically 3%, but can be increased to 6% or decreased for gabapentin-sensitive patients.
  • the transdermal vehicle Lipoderm® is used. This vehicle is a gel, but has the appearance and feel of a cream. It has the exceptional ability to contain up to 50% of its weight in active drugs. It is also cosmetically elegant and has a hypoallergenic compatibility with human dermis.
  • the combination of the 2 agents within the Lipoderm® base act synergistically to relieve neuropathic pain.
  • One method of preparation is as follows. Ketamine and gabapentin powders were filtered through a fine-mesh screen into the appropriate vessel (e.g., a glass mortar.) Powders were wetted with sufficient propylene glycol. Some Lipoderm® was added to suspend the wet powders. The remainder of Lipoderm® was added and triturated till mixed. Krisgel® 1% (of the total compound) was added to thicken. An ointment mill was used to completely mix and smooth the cream. The resulting cream looks and feels like custard.
  • Aqueous-Phase Solution Sorbitol solution, water, and PEG-100 stearate, were added to a Groen kettle (Model “TDB/8-20 CFC", Groen Division, Dover Corporation, Elk Grove Village, 111.).
  • the kettle has a self-contained water jacket. The temperature was maintained within the range of about 70° C. to about 80° C. The kettle was covered, and the mixture was heated and stirred. When a solution resulted, the methylparaben, ketamine hydrochloride, and gabapentin were added. Stirring and heating continued until all ingredients were dissolved.
  • Oil-Phase Solution Cetyl alcohol, isopropyl myristate, glycerol stearate and petrolatum were added to a stainless-steel container immersed in a hot water bath. The water-bath temperature was maintained in the range of 70° C. to 80° C. using a hot-plate. The solution was heated and stirred (Lab-Stirrer, Model LR 400 C, Fisher Scientific Inc., Pittsburgh, Pa.) until a homogenous liquid resulted. Propylparaben was then added and stirring and heating continued until the propylparaben was completely dissolved.
  • the oil phase (70° C.) was slowly poured into the aqueous phase (70° C.) and the resulting mixture stirred for 10 minutes using the kettle-stirring device.
  • the kettle stirring device was then disassembled and the mixture emulsified using a high-shear homogenizer (PowerGen Homogenizer, Model 700D, Fisher Scientific Inc., Pittsburgh, Pa.) for 15 minutes.
  • the kettle stirring device was reassembled to stir the resulting emulsion while the hot water in the kettle jacket was replaced with ice water to cool the emulsion.
  • simethicone was added and the emulsion was then mixed for another 15 minutes using the kettle-stirring device.
  • a Grisona MA filling machine (NAG Nahma AG, Unterageri, Austria) was used to fill the emulsion into 60 gram aluminum tubes (Peerless Tube Company, Bloomfield, N.J.).
  • the oil-phase-droplet diameters were measured via laser-light diffraction (Malvern Mastersizer S Laser Diffractor, Malvern Instruments Ltd, Malvem, UK). Prior to the analysis, emulsion samples were dispersed in a 6.5% solution of PEG-100 stearate in purified water. Sample refractive index and carrier-fluid refractive index were set at 1.5295 and 1.33, respectively. The default setting for the Presentation and Analysis Model is "OHD" and "Polydisperse”.
  • Gabapentin and ketamine hydrochloride were dissolved in the water in a glass beaker. Methylparaben and propylparaben were mixed with Transcutol-P in a separate beaker. The Transcutol-P solution containing the methylparaben and propylparaben was poured into the gabapentin/ketamine hydrochloride solution. A glass beaker containing the above solution was then placed inside a ice bath to cool the solution to approximately 5° C. Pluronic F 127 was added to the solution with continuous mixing (Lab-Stirrer, Model LR 400 C, Fisher Scientific Inc., Pittsburgh, Pa.) for approximately 12 hours until a clear solution resulted. While maintaining the temperature just below about 10° C, the clear solution was filled into aluminum tubes. When the solution temperature equilibrated to room temperature, it transformed into a clear gel.
  • compositions according to the invention are all combinations of Ketamine HCl and Gabapentin. They all share the trademarked name "Neurocreme”.
  • Example 4 Neurocreme 30% - 1 OQg example size
  • compositions described herein are applied two ways via massage: (1) directly to the pain site or appropriate ganglion and (2) into the appropriate dermatome on the spine.
  • Plan 1 was normally used first, especially if the pain locus is below the patient's waist line (due to reduced systemic circulation of the agents.) The patient is instructed to find the most precise area of pain — if possible — by using a blunt, pointed object (i.e., fingertip, pen tip, etc.) By use of a "checkerboard pattern" search, many times the pain locus is discovered. For example, a foot pain locus may be found by pressing a fingertip on one side of the ankle for approximately 2 seconds then moving the fingertip an inch towards the other side of the ankle. This pressure is repeated "checkerboard style"(across and downward) until the entire foot — top and bottom — has been covered.
  • a blunt, pointed object i.e., fingertip, pen tip, etc.
  • the patient takes note of what area(s) hurt most and then treats the area(s) with Vz gram or 1 gram of cream at each pain site. If a precise locus cannot be found, then a 1 gram dose to the ganglion located 3 A inch below and 3 A inch behind the inside anklebone will suffice.
  • This ganglion is responsible for innervation of the foot via the L-4, L-5, S-I , and S-2 dermatomes.
  • Other ganglia may be used similarly for pain loci at other anatomical sites.
  • An anesthesiologist or a medical professional with a thorough understanding of human anatomy — should be consulted for the most appropriate ganglion (or ganglia) to be used.
  • Plan 2 was used when there is insufficient analgesia provided by Plan 1.
  • Plan 2 requires massage of the cream into the appropriate dermatome on the spinal column.
  • the patient is shown where the correct dermatome application site (on the spine) is for the painful area described by the patient.
  • a foot pain locus requires cream application to the L-4, L-5, S-I, and S-2 vertebrae on the spine.
  • the dose may be increased by Vz gram increments daily. For example, if a 1-gram dose to the site did not relieve the pain during the first 3 days, then the dose would be increased by V 2 gram per application on day 4. If the pain was still not managed, the dose would be increased by another Vz gram dose on day 5. The dose total at that point would be 2 grams per application. This sequence would be repeated until (1) the pain is managed or (2) side effects begin. Note: Side effects at any time are the limiting factor for dosing. [0094] If Plan 1 does not provide sufficient analgesia within 7 days of the first application, then the patient is instructed to initiate Plan 2. Application to this area is explained above.
  • a 1 -gram dose at the correct dermatome is started with the proviso that the dose may be adjusted down or up after a 3 day dosing period. This is similar to Plan 1.
  • Dosing frequency is dependent on the cream's duration of action. Duration of action varies from patient to patient. Normally, the cream is applied 3 times daily, but more frequent — or less frequent — applications are possible. Again, the limiting factor is side effects. Hence, if no side effects, then multiple daily applications are OK. The cream is a pain management "tool". As such, the cream may be used as often as necessary (subject to side effects.)
  • Pain management is one objective of the compositions and methods described herein.
  • the methods and compositions described herein can ameliorate neuropathic pain in patients.
  • the compositions and methods described herein have the following advantages: (1) Surveys have shown that >75% of patients using the compositions described herein have managed their neuropathic pain with at least one embodiment described herein; (2) the compositions described herein are effective against a wide variety of sympathetically mediated pain (SMP) sources — including various neuropathies, low back pain, sciatica, and post-spinal surgery pain; (3) the doses needed to control neuropathic pain are relatively small (see survey, Table 1); (4) dose volumes are also small — a distinct application advantage; (5) patients affected by side effects total less than 22% (includes those who "failed” the cream); (6) the compositions described herein are cosmetically elegant; (7) the compositions described herein are easy to apply because they are readily absorbed by the prepared skin. TABLE 1
  • Table 1 above describes the most commonly used varieties of the compositions described herein.
  • a subjective 10-point pain scale was used by the patients at baseline and at 7 days to describe their pain.
  • a "1 " essentially meant no pain.
  • a "10” described very severe pain — the kind that leaves one in agony.
  • the amount applied was judged by the number of 1 gram — /4 gram dispensing spoons used per application.
  • Onset of analgesia for all four composition varieties share the same time period. These times varied from a half hour to over 72 hours. The onset times may differ from patient to patient.
  • 20 people used the 15% strength PLO-based (pluronic-lecithin organogel) transdermal gel but 3 reported treatment failure. This represents a success rate of 84%.
  • 19 patients who used this formulation represent a statistically small sample. This compound was applied to patients with degenerative disc disease, diabetic peripheral neuropathy, fibromyalgia, lower pack pain, myelitis - legs/feet, P/S neuropathy and postherpetic neuralgia.
  • the small sample size is representative but not indicative of the results of other patients. It is likely but not necessarily that greater amount of the NMDA antagonist may increase the amount of pain reduction and/or decrease the reported failures (e.g., via non-analgesia, or side effects).
  • the patients were treated for diabetic peripheral neuropathy, low back pain, polyneuropathy in the hands and feet, post-herpetic neuralgia, sciatica, CRPS/RSD, post-surgical neuropathy, and miscellaneous neuropathies including fibromyalgia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and can be administered to subjects to treat various neuropathies.

Description

TOPICAL FORMULATIONS FOR TREATMENT OF NEUROPATHY
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application 61/100,71 1 filed on September 27, 2008, the contents of which are hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION Field of the Invention
[0002] The present invention relates to methods and compositions for the topical treatment of neuropathy. More particularly, the present invention relates to topical compositions including a combination of ingredients that provides a surprising degree of effective relief from the symptoms of neuropathy with minimal side effects and to methods for administering topical compositions to treat neuropathy. Preferred embodiments contemplate chemical, biological or physical means of reducing such side effects.
Description of the Related Art
[0003] Peripheral neuropathy is a condition involving nerve-end damage anywhere in the body. Peripheral neuropathy generally refers to a disorder that affects the peripheral nerves, most often manifested as one or a combination of motor, sensory, sensorimotor, or autonomic neural dysfunction. The wide variety of morphologies exhibited by peripheral neuropathies can each be uniquely attributed to an equally wide variety of causes. For instance, peripheral neuropathies can be genetically acquired, can result from a systemic disease, can manifest as a post-surgical complication, or can be induced by a toxic agent. Some toxic agents that cause neurotoxicities are therapeutic drugs, antineoplastic agents, contaminants in foods or medicinals, and environmental and industrial pollutants. As much as 3% of the population is estimated to be affected, if not greater.
[0004] Although a number of neuropathies are related to the disease diabetes mellitus, others, although not known to be related to diabetes are similar in their physiological effects on the peripheral vascular system. Such diseases include Raynaud's Phenomenon, including CREST syndrome, autoimmune diseases such as erythromatosis, and rheumatoid diseases. Other peripheral neuropathies include the following: HIV-associated neuropathy; nutritional deficiency-associated neuropathy; cranial nerve palsies; drug-induced neuropathy; industrial neuropathy; lymphomatous neuropathy; myelomatous neuropathy; multi-focal motor neuropathy; immune- mediated disorders, chronic idiopathic sensory neuropathy; carcinomatous neuropathy; acute pain autonomic neuropathy; alcoholic neuropathy; compressive neuropathy; vasculitic/ischaemic neuropathy; mono- and polyneuropathies.
[0005] For example, among the most important toxic agents causing peripheral neuropathy are therapeutic agents, particularly those used for the treatment of neoplastic disease. In certain cases, peripheral neuropathy is a major complication of cancer treatment and is the main factor limiting the dosage of chemotherapeutic agents that can be administered to a patient (Macdonald, Neurologic Clinics 9:955-967 (1991)). This is true for the commonly administered agents cisplatin, paclitaxel and vincristine (Broun, et al., Am. J. Clin. Oncol. 16:18-21 (1993); Macdonald, Neurologic Clinics 9:955-967 (1991); Casey, et al., Brain 96:69-86 (1973)). The identification of methods for preventing or alleviating dose- limiting peripheral neuropathologic side effects would allow higher, and more therapeutically effective doses of these chemotherapeutics to be administered to patients, i.e., the therapeutic efficacy of such chemotherapeutics is typically a function of dose and therefore, increasing dosage provides increased patient survival (Macdonald, Neurologic Clinics 9:955-967 (1991); Oxols, Seminars in Oncology 16, suppl. 6:22-30 (1989))
[0006] The N-methyl-D-aspartate (NMDA) receptor seems to play a major role in neuropathic pain and in the development of opioid tolerance. Experiments in both animals and humans have established that NMDA antagonists such as ketamine and dextromethorphan can alleviate neuropathic pain and reverse opioid tolerance. Unfortunately, only a few NMDA antagonists are clinically available and their use is limited by unacceptable side effects.
[0007] Generally, depressed NMDA receptor function is associated with an array of negative symptoms. They sometimes induce "psychotomimetic" side effects, symptoms resembling psychosis. Such side effects caused by NMDA receptor inhibitors can include hallucinations, paranoid delusions, confusion, difficulty concentrating, agitation, convulsions, alterations in mood, nightmares (Muir, KW; Lees KR (1995), and may exhibit personality changes and disorganized thinking. "Clinical experience with excitatory amino acid antagonist drugs". Stroke 26 (3): 503-513.) catatonia (Aarts, MM; Tymianski M (2003). "Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors". Biochemical Pharmacology 66 (6): 877-886.) ataxia (Kim AH, Kerchner GA, and Choi DW. (2002). "Blocking Excitotoxicity". In CNS Neuroproteciton. Marcoux FW and Choi DW, editors. Springer, New York. Pages 3-36), anaesthesia (Kristensen, JD; Svensson B, and Gordh T Jr (1992). "The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans". Pain 51 (2): 249-253. PMlD 1484720.) and learning and memory deficits (Rockstroh, S; Emre M, Tarral A, and Pokorny R (1996). "Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans". Psychopharmacology 124 (3): 261-266.) In certain animals, such as rats, certain NMDA antagonists cause neurotoxicity and permanent brain injury (see, e.g., Olney J, Labruyerre J and Price MT. 1989. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, Volume 244, Issue 4910, Pages 1360-1362; Ellison G. 1995. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Research. Brain Research Reviews, Volume 20, Issue 2, Pages 250-267).
[0008] The use of ketamine transdermally in an organogel has shown some promise in the treatment of neuropathy. Because ketamine is an N-methyl-D-aspartate receptor antagonist it blocks a cascade of intracellular events that inhibit the hyper excitability of spinal cord neurons. Animal data show that certain spontaneous pains and allodynia have been treated successfully with Ketamine. Also, in humans, phantom limb pain has been treated with some success (Nadine & Bouhassira, Acta. Neurol. Scand 1999 (Supp 173): 12-24). Ketamine has been used experimentally to treat neuropathic pain by a variety of routes including the intravenous and subcutaneous. A topical form of low doses of Ketamine has shown some efficacy in treating painful neuropathy when other traditional medicines have failed. (Crowley et al., International Journal of Pharmaceutical Compounding 1998; 2:122-1273). [0009] Other compositions have been employed, including combinations of individual compounds. U.S. Pat. No. 6,387,957 (Frome) relates to the treatment of Sympathetically Mediated Pain (SMP), which include various neuropathies, employing the compounds ketamine (NMDA receptor antagonist), amitriptyline (antidepressant), and guanethidine (sympathetic blocking agent), in combination or independently. U.S. Patent Publication Nos. 2004/0204366 and 2004/0101582 attack the problem with a spectrum of analgesic compounds including combinations of ketamine, gabapentin and clonodine. Other solutions have attempted to increase the absorption of the compounds, see, e.g., US Patent Publication. No. 2004/0076648. Each of these references is incorporated herein by reference.
[0010] PCT Publication WO 9807447 describes combinations of anti-epileptic compounds, including gabapentin, with NMDA receptor antagonists. PCT Publications WO 9912537 and WO 0053225 describe combinations of NMDA antagonists and GABA analogs, including gabapentin and pregabalin. PC Publication WO 0200434 describes the use of NMDA antagonists in the treatment of central neuropathic pain. PCT Publication WO 05102390 describes alpha-2-delta ligands in combiation with NMDA antagonists as analgesics.
[0011] PCT Publication WO 03061656 describes a composition for treating disorders of the central nervous system comprising a GABA analog, such as gabapentin or pregabalin, with an NMDA receptor antagonist such as dextromethomorphan or d- methadone, optionally in combination with another pharmaceutically active substance.
[0012] PC Publications WO 9912537 and WO 0053225 describe combinations of anti-epileptic compounds, including gabapentin and pregabalin, in combination with NMDA antagonists as analgesics.
[0013] PC Publication WO 03091241 describes NR2B antagonists for a number of indications, together with alpha-2-delta ligands, e.g. gabapentin and pregabalin.
[0014] Accordingly, there remains a need in the art for effective treatments for neuropathies, and other neuropathic pains. SUMMARY OF THE INVENTION
[0015] In one aspect, the compositions described herein can provide for the treatment of peripheral neuropathy, and can include a therapeutically effective amount of at least one NMDA antagonist and one additional active compound in a pharmaceutically acceptable diluent or carrier suitable for topical or transdermal use. In one embodiment, the NMDA antagonist is provided in relatively high concentrations, such as greater than 15% by weight. NMDA antagonists may include, but are not limited to, PCP, nitrous oxide, ketamine, MK-801 , methadone, dextropropoxyphene, and ketobemidone.
[0016] In other aspects, methods described herein are directed to treating peripheral neuropathy, comprising the step of transdermal or topical administration of an effective amount of a pharmaceutical composition as described herein to the affected area of a subject in need of such treatment. Other drugs or ingredients may be added as needed to increase the analgesic effect or minimize the side effects.
[0017] In other embodiments, the peripheral neuropathy is a diabetic neuropathy. It will be clearly understood that the diabetic neuropathy may be associated with Type 1 (insulin-dependent) diabetes, Type 2 (non-insulin-dependent) diabetes, or both.
[0018] In some embodiments, the neuropathy is a non-diabetic neuropathy. Such a non-diabetic neuropathy may be genetically acquired, such as Charcot-Marie-Tooth syndrome. In other embodiments the peripheral neuropathy can result from a systemic or infectious disease such as HIV, or an infectious disease condition such as AIDS. In further embodiments, the peripheral neuropathy manifests as a post surgical complication.
[0019] In other embodiments the peripheral neuropathy is induced by a toxic agent. For example, the peripheral neuropathy can be caused by a chemotherapeutic agent such as paclitaxel (or other taxane derivative), vincristine, cisplatin, an agent used for the treatment of infectious diseases such as streptomycin, didanosine or zalcitabine, or any other chemically toxic agent. Infectious disease conditions such as post-polio syndrome or AlDS- associated neuropathy are specifically contemplated.
[0020] Other peripheral neuropathies include the following: HIV associated neuropathy; B12-deficiency associated neuropathy; cranial nerve palsies; drug-induced neuropathy; industrial neuropathy; lymphomatous neuropathy; myelomatous neuropathy; multi-focal motor neuropathy; chronic idiopathic sensory neuropathy; carcinomatous neuropathy; acute pan autonomic neuropathy; alcoholic neuropathy; compressive neuropathy; vasculitic/ischaemic neuropathy; mono- and poly-neuropathies.
[0021] In further embodiments, the neuropathy is due to low back pain, Guillain- Barre Syndrome, sciatica, or other chronic pain.
[0022] Further embodiments include methods for treating a subject suffering from peripheral neuropathy, the methods comprising topically administering an effective amount of the composition consisting essentially of ketamine and gabapentin formulated in a pharmaceutically acceptable topical carrier.
[0023] In an alternate embodiment, the methods comprise topically administering an effective amount of a composition comprising a NMDA antagonist formulated in a pharmaceutically acceptable carrier for topical treatment.
[0024] The compositions described herein can be administered in therapeutically effective amounts. A therapeutically effective amount means the amount required to at least partly to attain the desired effect, e.g., to effectively alleviate or prevent the symptoms of the peripheral neuropathy or pain, to mitigate the side effects of certain compounds such as neurotoxicity or psychosis or drowsiness, to effectuate or potentiate the activity of the invention composition, or combinations thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0025] In one aspect, the pharmaceutical compositions described herein can be used for the treatment of peripheral neuropathy. These compositions can include therapeutically effective amounts of at least one NMDA (receptor) antagonist and one additional active ingredient, such as gabapentin or clonidine which limits or mitigates the side effects of the NMDA (receptor) antagonist. In this embodiment the composition is formulated in a pharmaceutically acceptable diluent or carrier suitable for transdermal or topical use. Surprisingly, it was found that only one additional active ingredient was necessary to counteract the potential side affects of the NMDA (receptor) antagonist. Prior compositions used a plurality additional ingredients to counter the side effects of NMDA (receptor) antagonists. For example, prior compositions included ketamine, clonidine and gabapentin (See U.S. Publication 2004-0101582A1).
[0026] In one embodiment, the composition consists essentially of ketamine and gabapentin to treat neuropathy when the composition is administered topically in a physiologically acceptable vehicle. In one embodiment, the composition consists essentially of at least about 15% or 20% or more ketamine and at least about 3% gabapentin.
[0027] As used herein, the treatment of neuropathy refers to an anti-neuropathic response or a pain-reducing response elicited through the synergistic effect of the two compositions within each formulation as described herein, in which the combined effect of the two agents effectively mitigates, relieves, alleviates, reduces or removes the symptoms of peripheral neuropathy, provides a beneficial effect to the subject; and/or effectively mitigates or reduces the side effects associated with the NMDA-receptor antagonist. The compositions described herein may provide one or more of the following beneficial effects to a patient when topically applied in effective amounts: relief of pain, burning, tingling, electrical sensations and/or hyperalgesia. Also increased microcirculation, nitric oxide stabilization, and facilitated healing of skin ulcers and lesions. Additionally, protein kinase C inhibition, decreased oxidative stress, anti-inflammation, protection against radiation damage (particularly ultraviolet radiation), blockage of the formation of leukotrienes, stabilization of cell membranes, and/or promotion of the synthesis of nerves or nerve growth factor.
[0028] As used herein the meaning of "NMDA-receptor antagonist" or "NMDA antagonist" encompasses compounds that may block or inhibit the action of the N-methyl d- aspartate (NMDA) receptor. The receptor can be deactivated by inhibitors that can cause the NMDAR (NMDA receptor) to close by binding to allosteric sites, e.g., 1) Competitive antagonists, which bind to and block the binding site of the neurotransmitter glutamate; 2) glycine antagonists, which bind to and block the glycine site; 3) noncompetitive antagonists, which inhibit NMDARs by binding to allosteric sites; and 4) uncompetitive antagonists, which block the ion channel by binding to a site within it; or that block the NMDA receptor by another mechanism.
[0029] Examples of NMDA-receptor antagonists include, but are not limited to: Amantadine -"Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on
Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy", University Health
Network, Toronto, September 2005
Dextromethorphan - Wong BY, Coulter DA, Choi DW, Prince DA (1988).
"Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices". Neurosci. Lett. 85 (2): 261-6.
Dextrorphan - Wong BY, Coulter DA, Choi DW, Prince DA (1988). "Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N- methyl-D-aspartate in brain slices". Neurosci. Lett. 85 (2): 261-6. lbogaine - Popik P, Layer RT, Skolnick P (1994): "The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex." Psychopharmacology (Berl), 1 14(4), 672-4.
Ketamine - Harrison N, Simmonds M (1985). "Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex". Br J Pharmacol
84 (2): 381-91.
Nitrous oxide - Grasshoff C, Drexler B, Rudolph U, Antkowiak B (2006).
"Anaesthetic drugs: linking molecular actions to clinical effects". Curr. Pharm. Des.
12 (28): 3665-79; Kolesnikov et al. (1994) Life Sci. 55:1393. Administering inhibitors of nitric oxide synthase in morphine-tolerant animals reverses tolerance, despite continued opioid administration. Kolesnikov et al. (1993) Proc. Natl. Acad.
Sci. USA 90:5162.
Phencyclidine (PCP) -
Riluzole - Hugon J (1996). "ALS therapy: targets for the future". Neurology 47 (6
Suppl 4): S251^1.
Tiletamine - Ko JC, Smith TA, Kuo WC, Nicklin CF (1998). "Comparison of anesthetic and cardiorespiratory effects of diazepam-butorphanol-ketamine, acepromazine-butorphanol-ketamine, and xylazine-butorphanol-ketamine in ferrets".
Journal of the American Animal Hospital Association 34 (5): 407-16. Memantine (Axura, Akatinol, Namenda, Ebixa, l-amino-3,5-dimethylada-mantane) - Chawla, PS; Kochar MS (2006). "What's new in clinical pharmacology and therapeutics". WMJ 105 (3): 24-29.
Dizocilpine (MK-801) - Fix AS, Horn JW, Wightman KA, et al (1993). "Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex". Exp. Neurol. 123 (2): 204-15. Aptiganel (Cerestat, CNS-1102) - binds the Mg2+ binding site within the channel of the NMDA receptor.
Remacimide - Muir, KW (2005). "Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists". Current Opinion in Pharmacology 6 (1): 53-60. 7-chlorokynurenate - Hartley DM, Monyer H, Colamarino SA, Choi DW (1990). "7- Chlorokynurenate Blocks NMDA Receptor-Mediated Neurotoxicity in Murine Cortical Culture". Eur J Neurosci 2 (4): 291-295.
DCKA (5,7-dichlorokynurenic acid) - Frankiewicz T, Pile A, Parsons C (2000). "Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices". Neuropharmacology 39 (4): 631-^2.
Kynurenic acid - Khan MJ, Seidman MD, Quirk WS, Shivapuja BG (2000). "Effects of kynurenic acid as a glutamate receptor antagonist in the guinea pig". European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rh ino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 257 (4): 177-81. 1-Aminocyclopropanecarboxylic acid (ACPC)
AP7 (2-amino-7-phosphonoheptanoic acid) - van den Bos R, Charria Ortiz G, Cools A (1992). "Injections of the NMDA-antagonist D-2-amino-7-phosphonoheptanoic acid (AP-7) into the nucleus accumbens of rats enhance switching between cue- directed behaviours in a swimming test procedure". Behav Brain Res 48 (2): 165-70. APV (R-2-amino-5-phosphonopentanoate) - Abizaid A, Liu Z, Andrews Z, Shanabrough M, Borok E, Elsworth J, Roth R, Sleeman M, Picciotto M, Tschδp M, Gao X, Horvath T (2006). "Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite". J Clin Invest 1 16 (12): 3229-39.
• CPPene (3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-l-phosphonic acid) - Eblen F, Lόschmann P, Wϋllner U, Turski L, Klockgether T (1996). "Effects of 7- nitroindazole, NG-nitro-L-arginine. and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions". Eur J Pharmacol 299 (1-3): 9-16. [0030] Other NMDA-receptor antagonists include, but are not limited to, eliprodil; iamotrigine; flupirtine; celfotel; levemopamil; pyroloquinoline quinone; cis-4- (phosphonomethyl)-2-piperdine carboxylic acid; l-(4-hydroxy-phenyl)-2-(4-phenylsulfanyl- piperidin-l-yl)-pro pan- 1 -one; 2-[4-(4-fluoro-benzoyl)-piperidin-l-yl]-l-naphthalen-2-yl-et hanone (E 2001); 3-(l,l-dimethyl-heptyl)-9-hydroxyrnethyl-6,6-dimethyl-6a,7,8 ,10a- tetrahydro-6H-benzo[c]chromen-l-ol (HU-21 1); l-{4-[l -(4-chIoro-phenyl)-l-methyl-ethyl]- 2-methoxy-phenyl}-lH-[l,2,4]triazole-3carboxylic acid amide (CGP 31358); acetic acid 10- hy droxy-7,9,7',9'-tetramethoxy-3,3'-dimethyl-3,4,3, 4'-tetrahydro-lH,l 'H-
[5,5']bi[benzo[g]isochromenyl] -4-yl ester (ES 242-1); 14-hydroxy-l l-isopropyl-10-methyl- 5-octyl-10,13-diaza-tricyc lo[6.6.1.04,15]pentadeca-l ,4,6,8(15)-tetraen-12-one; and 4,5- dioxo-4,5-dihydro-lH-benzo[g]indole-2,7,9-tricarboxylic acid (PQQ), 3-((-)-
2carboxypiperazin-4-ylpropyl-l -phosphate (CPP); 1 -(cis-2-carboxypiperidine-4-yl)methyl-l - phosphonic acid (CGS 19755), D-2-Amrno-5-phosphonopentanoic acid (AP5); 2-amino- phosphonoheptanoate (AP7); D,L-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid carboxyethyl ester (CGP39551); 2-amino-4-methyl-5-phosphono-pent-3-enoic acid (CGP 401 16); (4-phosphono-but-2-enylamino)-acetic acid (PD 132477); 2-amino-4-oxo-5- phosphono-pentanoic acid (MDL 100,453); 3-((phosphonylmethyl)-sulfinyl)-D,L-alanine; amino-(4phosphonomethyl-phenyl)-acetic acid (PD 129635); 2-amino-3-(5-chloro- lphosphonomethyl-lH-benzoimidazol-2-yl)- propionic acid; 2-amino-3-(3- phosphonomethyl-quinoxalin-2-yl)-propionic acid; 2-amino-3-(5-phosphonomethyl- biphenyl-3-yl)-propionic acid (SDZ EAB 515); 2-amino-3-[2-(2-phosphono-ethyl)- cyclohexylj-propionic acid (NPC 17742); 4-(3-phosphono-propyl)-piperazine-2-carboxylic acid (D-CPP); 4-(3-phosphono-allyl)-piperazine-2-carboxylic acid (D-CPP-ene); 4- phosphonomethyl-piperidine-2carboxylic acid (CGS 19755); 3-(2-phosphono-acetyl)- piperidine-2-carboxylic acid (MDL 100,925); 5-phosphono-l ,2,3,4-tetrahydro-isoquinoline- 3-carboxylic acid (SC 48981); 5-(2-phosphono-ethyl)-l,2,3,4-tetrahydro-isoquinoline-3- carboxylic acid (PD 145950); όphosphonomethyl-decahydro-isoquinoline-S-carboxylic acid (LY 274614); 4-(lH-tetrazol-5ylmethyl)-piperidine-2-carboxylic acid (LY 233053 and 235723); ό-OH-Tetrazol-Sylmethyty-decahydro-isoquinoline-S-carboxylic acid (LY 233536); phencyclidine; thienylcyclohexylpiperidine (TCP); N-allylnormetazocine (SKF 10,047); cyclazocine; (l,2,3,4,9,9a-hexahydro-fluoren-4a-yl)-methyl-amine (PD 137889); (1, 3,4,9, 10,10a-hexahydro-2H-phenanthren-4a-yl)-methyl-amine (PD 138289); PD 138558; and quinoxalinediones, such as 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX); 6,7-dinitro- quinoxaline-2,3-dione (DNQX); spermine; spermidine; putrescine; arcaine; PEAQX; PPDA; hodgkinsine; dexoxadrol; endopsychosin; etoxadrol; eticyclidine,; rhynchophylline; rolicyclidine; tenocyclidine; xenon; 7-chlorokynurenate; CGP-39653; DCKA; kynureneic acid; L-689,560; CP-101,606; ifenprodil; Ro25-6981 ; and the like. References that disclose other NMDA-receptor antagonists as well as assays for identifying NMDA-receptor antagonists include Jia-He Li, et al., 38 J. Med. Chem. 1955 (1995); Bigge 45 Biochem. Pharmacol. 1547 (1993); Steinberg et al, 133 Neurosci. Lett. 225 (1991); Meldrum et al., 1 1 Trends Pharmacol. Sci., 379 (1990); Willetts et al., 1 1 Trends Pharmacol. Sci. 423 (1990); Faden et al., 13 Trends Pharmacol. Sci. 29 (1992); Rogawski 14 Trends Pharmacol. Sci. 325 (1993); Albers et al, 15 Clinical Neuropharm. 509 (1992); Wolfe et al., 13 Am. J Emerg. Med., 174 (1995); and Bigge, 45 Biochem. Pharmacol. 1547 (1993); U.S. Pat. Nos. 6,251,948 (issued Jun. 26, 2001); U.S. Pat. No. 5,985,586 (issued Nov. 16, 1999), and U.S. Pat. No. 6,025,369 (issued Feb. 15, 2000); Jacobson et al., 1 10 J. Pharmacol. Exp. Ther. 243 (1987); and Thurkaufet al., 31 J. Med. Chem. 2257 (1988), PCT App. No. WO/2004/045601 , all of which citations are hereby expressly incorporated herein by reference.
[0031] The NMDA antagonist may be an NMDA antagonist that would not be considered for general clinical use by itself, particularly in higher amounts or usage, due to its side effects. In some embodiments, the NMDA antagonist is a non-competitive channel blocker such as PCP, nitrous oxide, ketamine, MK-801, dextromethorphan, amantadine, dextromethorphan, ibogaine, ketamine, norketamine, memantin, riluzole, tiletamine, dextrorphan, and phencyclidine, and the like. Other compounds with NMDA receptor antagonist activities that are existing pharmaceuticals or nutraceuticals (e.g., have undergone one or more regulatory trials in humans or animals (e.g., FDA based Phase I, Phase II and/or Phase III trials) are also within the scope of the invention. In one embodiment, the NMDA- receptor antagonist described herein is a non-competitive NMDA-receptor antagonist, more preferably, ketamine or norketamine, even more preferably, ketamine hydrochloride.
[0032] Ketamine is an N-methyl-D-aspartate (NMDA) calcium channel antagonist that can be admixed in the compositions described herein in concentrations ranging from 10-50%, preferably 10 to 40%, and most preferably from 15% to 20% or to 25% - 30%. In some embodiments, the topical formulation has about 15% ketamine. In some embodiments, the topical formulation has about 20% ketamine. In some embodiments, the topical formulation has about 25% ketamine.
[0033] In general, the amount of NMDA-receptor antagonist in the compositions of the invention is within the range of from about 0.1 percent to about 100 percent of the total weight of the composition, more preferably, of from about 3 percent to about 50 percent of the total weight of the composition. More preferably, the range is from about 10 percent to about 40 percent of the total weight, and includes the ranges, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40. For example, the amount of ketamine in the invention composition is within the range of from about 5% to about 40%, more preferably from about 10% to about 40, more preferably from about 15% to about 30%, even more preferably from about 20% to about 25%, or alternatively, greater than 10% or 15%. Such ranges of NMDA antagonist employed in the present invention would likely, prior to applicant's disclosure, be considered too high for clinical application, e.g., too high for one time use or, alternatively, too high for repeated use particularly on a large population of patients.
[0034] Without being bound to any particular theory of mechanism, the compositions described herein provide an effective antineuropathic response through two compounds that in combination provide effective analgesia with a low or reduced side effect profile. For example, the formulations in combination would provide a lower side effect profile than the individual components taken independently, particularly in higher concentrations or dosages. Other properties which may be considered is the effective half life of the composition, the ability to cross or not cross the blood brain barrier, the ability of the compound to remain local in proximity to the topical administration, increase or decrease in blood pressure, psychomimetic symptoms, drowsiness, and the like. Those of skill in the art will recognize compounds and side effect profiles of compounds suitable in the present invention.
[0035] As used herein, the phrase "side effects" encompasses unwanted and adverse effects of a therapy (e.g., a prophylactic or therapeutic agent). An adverse effect from a therapy (e.g., prophylactic or therapeutic agent) might be harmful or uncomfortable or risky. Side effects include, but are not limited to fever, chills, lethargy, gastrointestinal toxicities (including gastric and intestinal ulcerations and erosions), nausea, vomiting, neurotoxicities, psychotomimetic effects, nephrotoxicities, renal toxicities (including such conditions as papillary necrosis and chronic interstitial nephritis), hepatic toxicities (including elevated serum liver enzyme levels), myelotoxicities (including leukopenia, myelosuppression, thrombocytopenia and anemia), dry mouth, metallic taste, prolongation of gestation, weakness, somnolence, pain (including muscle pain , bone pain and headache), hair loss, asthenia, dizziness, extra pyramidal symptoms, akathisia, cardiovascular disturbances and sexual dysfunction.
[0036] Many drugs have been found that lessen the risk of neurotoxicity from NMDA receptor antagonists that can used as the second active compound within the formulations described herein in order to reduce unwanted side effects. Centrally-acting alpha-2 agonists such as clonidine and guanfacine are thought to most specifically target the etiology of NMDA neurotoxicity (see, e.g., US Pat. App. Nos. 20050148673, 20050222270, 20020068754 and 20020016319, and PCT App. No. WO/2001/089448A2). Other drugs acting on various neurotransmitter systems known to inhibit NMDA antagonist neurotoxicity include: anticonvulsants or antiepileptics, anticholinergics (see, e.g., US Pat. No. 5034400, 5616580, 5605911, 5767130 and 5902815), tri-cyclo-alkyl-amine (TCAA) structure (US Pat. No. 20020177592) diazepam, barbiturates [Olney J, Labruyere J, Wang G, Wozniak D, Price M, Sesma M (1991). "NMDA antagonist neurotoxicity: mechanism and prevention". Science 254 (5037): 1515-8; US Pat. No. 5474990], ethanol [Farber NB, Heinkel C, Dribben WH, Nemmers B, Jiang X. (2004). "In the adult CNS, ethanol prevents rather than produces NMDA antagonist-induced neurotoxicity". Brain Res 1028(l):66-74], 5-HT2A serotonin agonists [Farber N, Hanslick J, Kirby C, McWilliams L, Olney J (1998). "Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity". Neuropsychopharmacology 18 (1): 57-62.], risperidone and muscimol [Maas, Al (2001). "Neuroprotective agents in traumatic brain injury". Expert Opin Investig Drugs. 10(4):753- 67; Tryba M, Gehling M. Clonidine— a potent analgesic adjuvant. Curr Opin Anaesthesiol. 2002 Oct;15(5):51 1-7].
[0037] The anticonvulsants, also called antiepileptic drugs (abbreviated "AEDs"), belong to a diverse group of pharmaceuticals used in prevention of the occurrence of epileptic seizures. Anticonvulsants are also increasingly finding ways into the treatment of bipolar disorder, since many seem to act as mood stabilizers. The goal of an anticonvulsant is to suppress the rapid and excessive firing of neurons that start a seizure. Failing this, a good anticonvulsant would prevent the spread of the seizure within the brain and offer protection against possible excitotoxic effects that may result in brain damage. Certain anticonvulsants prevents Olney vacuole formation neurotoxicity of MK-801, an NMDA antagonist, when injected into female rats, see Farber, N B, et al. "Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity." MoI Psychiatry 2002; 7(7): 726-733.
[0038] Examples of useful anticonvulsants include, but are not limited to, acetylpheneturide, albutoin, aloxidone, aminoglutethimide, 4-amino-3-hydroxybutyric acid, atrolactamide, beclamide, buramate, calcium bromide, carbamazepine, cinromide, clomethiazole, clobazam, clonazepam, decimemide, diethadione, dimethadione, doxenitroin, eterobarb, ethadione, ethosuximide, ethotoin, felbamate, fluoresone, fosphenytoin, gabapentin, 5-hydroxytryptophan, lamotrigine, levetiracetam, magnesium bromide, magnesium sulfate, mephenyloin, mephobarbital, metharbital, methetoin, methsuximide, 5- methyl-5-(3-phenanthryl)-hydantoin, 3-methyl-5-phenylhydantoin, narcobarbital, nimetazepam, nitrazepam, oxcarbazepine, paramethadione, phenacemide, phenetharbital, pheneturide, phenobarbital, phensuximide, phenylmethylbarbituric acid, phenytoin, phethenylate sodium, potassium bromide, pregabalin, primidone, progabide, sodium bromide, sodium valproate, solarium , strontium bromide, suclofenide, sulthiame, tetrantoin, tiagabine, topiramate, trimethadione, valproate semisodium, valproic acid, valpromide, vigabatrin, and zonisamide, and derivatives thereof.
[0039] Gabapentin is a glutamate antagonist at the NMDA and AMPA (sodium channel) receptor sites. This agent can be admixed in strengths ranging from 1 to 30 percent, preferably strengths less than 15%, more preferably in strengths 10% or less, including in 1 , 2, 3, 4, 5, 6, 7 and 8%. In one embodiment, the formulation has 3% - 6% gabapentin, but it can be included in amounts of 1%, 2%, 4%, 5%, 7%, 8%, 9%, or therebetween. More dosing flexibility is allowed transdermally because of its relatively low systemic concentration. See Bakonja M, Baydoun A, Edwards K R, et al. "Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus — a randomized controlled trial." JAMA 1998; 280: 1831 -1836. Also see Rowbatham M, Hardin N, Stacey B, et al. "Gabapentin for the treatment of postherpetic neuralgia — a randomized controlled trial." JAMA 1998; 280: 1837-1842.
[0040] In an alternative embodiment of the compositions described herein, other active components can be used to potentiate the action of NMDA -receptor antagonists such as ketamine. For example, analgesics can be any known in the art, including, but not limited to NMDA ligands, AMPA ligands, non-NMDA or AMPA ligands, TNF-I α ligand, GABA ligand, α-2 ligands, and the like. Such analgesics can include clonidine, capsaicin, lidocaine, bupivacaine, mepivacaine, ropivacaine, tetracaine, etidocaine, chloroprocaine, prilocaine, procaine, benzocaine, dibucaine, dyclonine hydrochloride, pramoxine hydrochloride, benzocaine, lacosamide and proparacaine. It is preferable that the topical formulation have as little of a side effect profile for a large population of patients.
[0041] In addition, the compositions described herein can further comprise additional ingredients that can increase the analgesic effectiveness of the combination of invention composition. Such ingredients can facilitate the effect of this combination or compounds by increasing absorption and/or penetration, provide for a more comprehensive pain management regimen, decrease the side effect profile of the base composition, or the like. For example, magnesium ions (e.g., from magnesium oxide or other magnesium preparations) antagonize ionic calcium in the nervous system, enhancing the effect of the present invention. Those of skill in the art will readily recognize additional ingredients that can be admixed in the compositions described herein.
[0042] In some compositions, co-administration with a magnesium salt may increase the pain-relieving efficacy of this treatment in at least some cases. As used herein, the term "salt" includes any compound or complex that releases substantial quantities of free magnesium ions (Mg ++) when dissolved in an aqueous solution.
[0043] Nerve impulse conduction is blocked by a decrease in nerve cell membrane permeability to sodium ions, possibly by competing with calcium-binding sites that control sodium permeability. This change in permeability results in decreased depolarization and an increased excitability threshold that ultimately prevents the nerve action potential from forming.
[0044] Ionic calcium is antagonized by magnesium ions in the nervous system. Because of this, dietary supplements of magnesium oxide and other magnesium preparations may increase or enhance the effects of calcium channel blockade.
[0045] Magnesium can effect muscle relaxation through direct action on the cell membrane. Mg++ ions close certain types of calcium channels, which conduct a positively charged calcium ion into the neuron. With an excess of magnesium, more channels will be blocked and the nerve will have less activity.
[0046] The compositions described herein can further comprise non- physiologically active ingredients or components usually admixed in such topical preparations (besides an NMDA antagonist and a second active ingredient, such as an anticonvulsant). For example, the compositions may also include additional ingredients such as other carriers, moisturizers, oils, fats, waxes, surfactants, thickening agents, antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives, perfumes, dyestuffs, lower alkanols, humectants, emollients, dispersants, sunscreens such as radiation blocking compounds or particularly UV-blockers, antibacterials, antifungals, disinfectants, vitamins, antibiotics, or other anti-acne agents, as well as other suitable materials that do not have a significant adverse effect on the activity of the topical composition. Additional inactive ingredients for inclusion in the carrier may be sodium acid phosphate moisturizer, witch hazel extract carrier, glycerin humectant, apricot kernel oil emollient, corn oil dispersant, and the like which are further detailed below. Those of skill in the art will readily recognize additional inactive ingredients, which can be admixed in the compositions described herein.
[0047] In addition to the foregoing components, the compositions described herein can optionally contain other ingredients. For example, triethanolamine can be added as a crosslinking agent. A preservative, such as betahydoxytoluene can also be added. Other irritation reducing agents can be added too. In this regard, irritation reducing agents can include, but are not limited to, glycerol. In some instances, semi-solid testosterone formulations have been prepared with propylene glycol and/or butylene glycol as the glycol component, ethyl alcohol and/or isopropyl alcohol as the alcohol component. Preservatives, a cross-linking agent, and additional irritation reducing agents can be included in formulations prepared in accordance with the methods described.
[0048] The compositions and methods of the invention are effective to induce local anaelgesia and to treat neuropathic pain. As used herein the term "neuropathic pain" refers to neuropathic-pain syndromes, that is, pain due to lesions or dysfunction in the nervous system. The compositions and methods of the invention can be used to treat or prevent pain related to or induced by the following diseases, trauma, or conditions: general neuropathic conditions, such as peripheral neuropathy, phantom limb pain, reflex- sympathetic dystrophy, causalgia, syringomyelia, and painful scar; specific neuralgias at any location of the body; back pain; diabetic neuropathy; alcoholic neuropathy; metabolic neuropathy; inflammatory neuropathy; chemotherapy-induced neuropathy, herpetic neuralgias; traumatic odontalgia; endodontic odontalgia; thoracic-outlet syndrome; cervical, thoracic, or lumbar radiculopathies with nerve compression; cancer with nerve invasion; traumatic-avulsion injuries; mastectomy, thoracotomy pain; spinal-cord-injury; stroke; abdominal-cutaneous nerve entrapments; tumors of neural tissues; arachnoiditis; stump pain; fibromyalgia; regional sprains or strains; myofascial pain; psoriatic arthropathy; polyarteritis nodosa; osteomyelitis; burns involving nerve damage; AIDS-related pain syndromes; connective tissue disorders, such as systemic lupus erythematosis, systemic sclerosis, polymyositis, and dermatomyositis; and inflammatory conditions, such as acute inflammation (e.g. trauma, surgery and infection) or chronic inflammation (e.g., arthritis and gout). [0049] The term "active", "active compound" or "active ingredient" means a compound or ingredient that exerts a physiological affect. For example, compounds that reduce, eliminate, or alleviate the side effects of an NMDA-receptor antagonist would be active compounds. Inactive compounds or ingredients are those that do not exert a physiological effect on a patient or subject or do not reduce, eliminate, or alleviate side effects of NMDA-receptor antagonists.
[0050] Topical application of the composition may be useful for relieving pain, inflammation and irritation associated with skin diseases and disorders, such as psoriasis, pruritus, and lesions. Painful lesions develop, for example, from viral infections, skin cancers and genetic disorders. Topical application of the composition provides relief from pain associated with wounds, insect and animal bites, abrasions and burns, including those resulting from over-exposure to the sun, chemicals, radiation or chemotherapeutic agents. Acute post-operative or surgical pain can be reduced or even prevented, as can pain associated with chronic disorders, such as arthritis.
[0051] In some embodiments the methods described herein can provide a treatment of applying the compositions described herein to an affected area of a subject with diabetic polyneuropathy. In other aspects, the methods described herein can include treating peripheral neuropathy, comprising the step of topical administration of a pharmaceutical composition of ketamine in a topical vehicle to the affected area of a subject in need of such treatment.
[0052] Thus, the methods and compositions described herein can be effective for neuropathies, particularly peripheral neuropathies, associated with diseases such as: uremia; childhood cholestatic liver disease; chronic respiratory insufficiency; alcoholic polyneuropathy; multiple organ failure; sepsis; hypoalbuminemia; eosinophilia-myalgia syndrome; hepatitis; porphyria; hypoglycemia; vitamin or nutritional deficiency (e.g., B-12 deficiency); chronic liver disease; primary biliary cirrhosis; hyperlipidemia; leprosy; Lyme disease; herpes zoster; Guillain-Barre syndrome; chronic inflammatory demyelinating polyradiculoneuropathy; sensory perineuritis; HIV or acquired immunodeficiency syndrome (AIDS) — associated neuropathy; Sjogren's syndrome; primary vasculitis (such as polyarteritis nodosa); allergic granulomatous angiitis; hypersensitivity angiitis; Wegener's granulomatosis; Raynaud's Phenomenon, including CREST syndrome, autoimmune diseases such as erythromatosis (systemic lupus erythematosis); rheumatoid arthritis or other rheumatoid diseases; mixed connective tissue disease; scleroderma; sarcoidosis; vasculitis; systemic vasculitides; acute tunnel syndrome; pandysautonomia; primary, secondary, localized or familial systemic amyloidosis; hypothyroidism; chronic obstructive pulmonary disease; acromegaly; malabsorption (sprue, celiac disease); carcinomas (sensory, sensorimotor, late and demyelinating); lymphoma (including Hodgkin's), polycythemia vera; multiple myeloma (lytic type, osteosclerotic, or solitary plasmacytoma); benign monoclonal gammopathy; macroglobulinemia; cryoglobulinemia; tropical myeloneuropathies; herpes simplex infection; cytomegalovirus infection; cranial nerve palsies; drug-induced neuropathy; industrial neuropathy; lymphomatous neuropathy; myelomatous neuropathy; multi-focal motor neuropathy; immune- mediated disorders, chronic idiopathic sensory neuropathy; carcinomatous neuropathy; acute pain autonomic neuropathy; alcoholic neuropathy; compressive neuropathy; vasculitic/ischaemic neuropathy; mono- and polyneuropathies; and diabetes.
[0053] Genetically acquired neuropathies suitable for treatment by the methods and compositions described herein include, without limitation: peroneal muscular atrophy (Charcot-Marie-Tooth Disease) hereditary amyloid neuropathies, hereditary sensory neuropathy (type I and type II), porphyric neuropathy, hereditary liability to pressure palsy, Fabry's Disease, adrenomyeloneuropathy, Riley-Day Syndrome, Dejerine-Sottas neuropathy (hereditary motor-sensory neuropathy-Ill), Refsum's disease, ataxia-telangiectasia, hereditary tyrosinemia, anaphalipoproteinemia, abetalipoproteinemia, giant axonal neuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy, and Friedrich's ataxia.
[0054] In alternative embodiments compositions described herein are directed to treatment of neuropathic pain, especially pain caused by nerve injury or sympathetically mediated pain. Sympathetically mediated pain (SMP) is a type of pain in which over activity of the sympathetic nervous system plays a crucial role. It includes the syndromes of reflex sympathetic dystrophy (RSD), causalgia, neuropathic pain secondary to nerve injury, and pain from neuromas. It encompasses all neurogenic pain that is not central and is related to a nerve injury regardless of the cause. Neuropathic pain syndromes include, without limitation (other than the neuropathies described herein), allodynia, various neuralgias such as post herpetic neuralgia and trigeminal neuralgia, phantom limb pain, hyperpathia, hyperesthesia, hyperalgesia, dyesthesia, paresthesia, anesthesia delorosa, deafferatation pain, and complex regional pain syndromes (CRPS), such as reflex sympathetic dystrophy (RSD) and causalgia. Specific examples include low back pain, sciatica, Guillain-Barre Syndrome, post-surgical traumatic neuropathy, and diabetic peripheral polyneuropathy.
Formulations
[0055] The formulations in which the compositions described herein are incorporated can assume any of a variety of dosage forms, including solutions, suspensions, ointments, and solid inserts. Examples are creams, lotions, gels, ointments, suppositories, sprays, foams, liniments, aerosols, buccal and sublingual tablets, various passive and active topical devices for absorption through the skin and mucous membranes, including transdermal applications, and the like.
[0056] Typical pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or vegetable oils, and water-soluble ophthalmologically acceptable non-toxic polymers, for example, cellulose derivatives such as methylcellulose. A typical cream or ointment-type carrier for topical application that can be used according to the methods and compositions described herein include a mixture of water, glycerin, propylene glycol, and methylparaben. Topical carriers may also include other conventional emulsifiers and emollients including alginates, glyceryl stearate, PEG-100 stearate, cetyl alcohol, propylparaben, butylparaben, sorbitols, polyethoxylated anhydrosorbitol monostearate (TWEEN), white petrolatum (VASELINE), triethanolamine, Emu oil, aloe vera extract, lanolin, cocoa butter, and the like. Suitable topical carriers are well known to the skilled artisan.
[0057] Preferably, Lipoderm® (Professional Compounding Centers of America, Houston, Tex.) is admixed in the compositions described herein. Alternative ointment bases are known to persons skilled in the art such as Transcutol-P (ethoxydiglycol, commercially available, for example, from Gattefosse, Westwood, NJ). Sufficient Lipoderm® base is admixed to act as a carrier for the active ingredients of the composition. Typically the Lipoderm® base will make up more than about 50% of the total composition and more preferably about 70% of the composition is the Lipoderm® base. The Lipoderm® base functions as a carrier and enhances penetration through the skin. It is also hypoallergenic and is aesthetically pleasing.
[0058] The terms "matrix," "matrix system," or "matrix patch" relate to an active permeant or drug dissolved or suspended in a biocompatible polymeric phase, preferably a pressure sensitive adhesive, that can also contain other ingredients or in which the enhancer is also dissolved or suspended. This definition is meant to include embodiments wherein such polymeric phase is laminated to a pressure sensitive adhesive or used with an overlay adhesive. A matrix system usually and preferably comprises an adhesive layer having an impermeable film backing laminated onto the distal surface thereof and, before transdermal application, a release liner on the proximal surface of the adhesive. The film backing protects the polymeric phase of the matrix patch and prevents release of the drug and/or enhancer to the environment. The release liner functions similarly to the impermeable backing, but is removed from the matrix patch prior to application of the patch to an application situs. Matrix patches are known in the art of transdermal drug delivery to routinely contain such backing and release liner components, and matrix patches according to the compositions described herein should be considered to comprise such backing and release liner or their functional equivalents. U.S. Pat. No. 5,122,383 (incorporated herein by reference) describes such backing and release liner. A matrix system therefore relates to a unit dosage form of a drug composition in a polymeric carrier, also containing the enhancer and other components that are formulated for maintaining the drug composition in the polymeric layer in a drug transferring relationship with the derma, i.e. the skin or mucosa. A matrix patch is distinguished from a "liquid reservoir patch," wherein an active permeant or drug is dissolved in a gelled liquid contained in an occlusive device having an impermeable back surface and an opposite surface configured appropriately with a permeable membrane and adhesive for transdermal application, e.g., U.S. Pat. No. 4,983,395, incorporated herein by reference in its entirety. [0059] A typical transdermal formulation comprises a conventional aqueous or non-aqueous vehicle, for example, a cream, ointment lotion or paste or in the form of a medicated plaster, patch or membrane.
[0060] The term "effective amount" of a drug or permeant relates to a nontoxic but sufficient amount of a compound to provide the desired local or systemic effect without adverse side effects. An "effective amount" of permeation enhancer as used herein relates to an amount selected so as to provide the desired increase in membrane permeability and, correspondingly, the desired depth of penetration, rate of administration, and amount of drug.
[0061] As used herein, "application situs" relates to a site suitable for topical application with or without the means of a device, patch, or dressing, e.g. the spinal column, behind the ear, on the arm, back, chest, abdomen, leg, top of foot, etc. For example, the cream can be applied to the site of pain or the spine dermatome(s) of the pain site, e.g., L2-S2 for any leg, knee, or foot neuropathy.
[0062] As used herein, transdermal delivery also includes numerous different systems for the transdermal delivery of active agents known in the art. Transdermal delivery systems include but are not limited to passive devices such as drug-in-adhesive transdermal patches and "active" transdermal technologies such as iontophoresis, electroporation, sonophoresis, magnetophoresis, microneedle devices and those devices that use thermal energy to make the skin more permeable.
[0063] Transdermal drug delivery devices are available from the 3M Drug Delivery Systems Division (St. Paul, Minn., USA), Noven Pharmaceuticals, Inc. (Miami, FIa., USA), ImaRx (Tucson, Ariz., USA), Elan Corporation (Dublin, Ireland), Novosis AG (Miesbach, Germany), Ultrasonic Technologies (St. Albans, Vt., USA), Antares Pharma (Exton, Pa., USA), Altea Therapeutics (Tucker, Ga., USA), Iomed, Inc. (Salt Lake City, Utah, USA), MacroChem Corp (Lexington, Mass., USA), Sontra Medical Corporation (Franklin, Mass., USA), Vyteris, Inc. (Fair Lawn, NJ. , USA), BioChemics, Inc. (Danvers, Mass., USA), A.P Pharma (Redwood, City, Calif., USA), MIKA Pharma GmbH (Limburgerhof, Germany), NexMed, Inc. (Robbinsville, N.J., USA), Encapsulation Systems, Inc. (Springfield, Pa., USA), Acrux Ltd (Elgin, 111., USA), Jenapharm GmbH (Berlin, Germany), Norwood Abbey (Victoria, Australia), Novavax (Columbia, Md., USA), Genetronics Biomedical Corporation (San Diego, Calif., USA), Adherex Technologies (Research Triangle Park, N.C., USA), and AlphaRx (Ontario, Canada).
Penetration Enhancers
[0064] In another embodiment, the compositions of the invention can further comprise inactive compounds, such as penetration enhancers. When present in a composition of the invention, the amount of penetration enhancer is preferably from about 1% to about 10% by weight of the total composition weight, more preferably from about 2% to about 5% by weight.
[0065] Penetration enhancers can be included in some embodiments to optimize transfer of the NMDA-receptor antagonist through the stratum comeum and into the dermis/dermatome to provide a local effect. For a discussion of use of penetration enhancers in topical formulations see generally, Percutaneous Penetration Enhancers (Eric W. Smith & Howard I. Maibach eds. 1995); Ghosh, T. K. et al. 17 Pharm. Tech. 72 (1993); Ghosh, T. K. et al. 17 Pharm. Tech. 62 (1993); Ghosh, T.K. et al. 17 Pharm. Tech. 68 (1993), all of which citations are hereby incorporated herein by reference. The penetration enhancer should be pharmacologically inert, non-toxic, and non-allergenic, have rapid and reversible onset of action, and be compatible with the compositions of the invention.
[0066] Examples of penetration enhancers include, but are not limited to, transcutol P, ethyl alcohol, isopropyl alcohol, lauryl alcohol, salicylic acid, octolyphenylpolyethylene glycol, polyethylene glycol 400, propylene glycol, N- decylmethylsulfoxide, DMSO and the azacyclo compounds, as disclosed in U.S. Pat. Nos. 4,755,535; 4,801,586; 4,808,414; and 4,920,101 , all of which patents are hereby expressly incorporated herein by reference. Preferably, the penetration enhancer is transcutol P.
Methods of Manufacture
[0067] The compositions of the invention are prepared according to standard methods, well known in the art, for preparing emulsions for topical administration. For example, the methods recited in Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams & Wilkins (2006), hereby expressly incoφorated herein by reference, can be used. Also, Example preparations are recited in the Example section below.
[0068] The compositions described herein can be made by cold compounding. This is significant since one or more of the compounds admixed in the topical compositions described herein may be sensitive to heat or other types of energy. Thus the activity of the composition may be detrimentally affected as a result of the formulation of the compositions in other manners. Preferably, the ingredients of this topical composition can be merely mixed together, without heating and using a sufficient amount of the carrier to provide a substantially homogeneous cream or gel. It is generally preferred to dissolve, disperse or suspend one or more of the ingredients prior to cold compounding in order to ensure substantially homogeneous distribution of the active ingredients in the composition.
[0069] Alternatively, the components can be separated into those that are water- soluble and those that are oil-soluble. The water-soluble components can be mixed together in one vessel to form a solution and the oil-soluble components can be mixed together in a separate vessel and heated (e.g., 70° C. to 80° C.) to form a solution. The two solutions can then be mixed and the mixture allowed to cool. This method requires nothing more than two beakers and a heating apparatus. Homogenation is achieved using a high-shear rate blender or other suitable apparatus. The appropriate droplet size is achieved by standard adjustment of the shear rate during high-speed mixing followed by droplet size analysis as described in Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams & Wilkins (2006) and Allen & Terence, Particle Size Measurement 483 (4th ed. 1990, both or which citations are hereby expressly incorporated herein by reference. Suitable equipment and methods for preparing emulsions and compositions of the invention, such as high-shear rate blenders are described in 2 Remington: The Science and Practice of Pharmacy 1509-1515 (Alfonso R. Gennaro ed., 19th ed. 1995) (updated in Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 21 st edition, Lippincott, Williams & Wilkins (2006)), hereby expressly incorporated herein by reference. Methods for preparation of emulsions for topical administration, suitable for preparing compositions of the invention, are also described in Bernard Idson, Pharmaceutical Emulsions in 1 Pharmaceutical Dosage Forms: Disperse Systems 199 (Herbert A. Lieberman et al. eds. 1988), hereby expressly incorporated herein by reference.
[0070] The compositions are then packaged and stored according to well-known methods. For example, see the packaging procedures described in 1 Remington: The Science and Practice of Pharmacy 390-391 (Alfonso R. Gennaro ed., 19th ed. 1995 - updated in Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams & Wilkins (2006)), hereby incorporated herein by reference. If desired, the compositions of the invention can be sterilized according to well-known methods, for example, the methods described in 2 Remington: The Science and Practice of Pharmacy 1463-1486 (Alfonso R. Gennaro ed., 19th ed. 1995 - updated in Gennaro, A. R., Remington: The Science and Practice of Pharmacy, 21 st edition, Lippincott, Williams & Wilkins (2006)), hereby incorporated herein by reference.
[0071] Concentrations, amounts, and other numerical data may be expressed or presented herein in a range format. It is to be understood that such a range format is used merely for convenience and brevity and thus should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub- range is explicitly recited. As an illustration, a numerical range of "about 15% to about 30%" should be interpreted to include not only the explicitly recited values of about 15 % to about 30%, but also include individual values and subranges within the indicated range. Thus, included in this numerical range are individual values such as 15, 16, 17, 18, 19., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30, and sub-ranges such as from 15 to 25, 20 to 25, and from 20 to about 30, etc. This same principle applies to ranges reciting only one numerical value. Furthermore, such an interpretation should apply regardless of the breadth of the range or the characteristics being described.
Application
[0072] The general mode of action of the composition is through "topical administration." The term "topical administration" or "topical application" refers to directly layering or spreading upon epidermal tissue, especially outer skin or membrane, including but not limited to the skin or membrane of cutaneous, mucosal or oral, vaginal, rectal, ocular, or nasal surfaces or cavities. The composition is topically administered to a subject in an amount and duration sufficient to prevent or relieve pain associated with any cause, including, but not limited to, neuropathic inflammation, and acute and chronic peripheral neuropathy.
[0073] Examples of patches suitable for use with compositions of the invention include (1) the matrix-type patch; (2) the reservoir-type patch; (3) the multi-laminate drug-inadhesive type patch; (4) the monolithic drug-in-adhesive type patch; and (5) hydrogel patch; see generally Ghosh, T. K.; Pfister, W. R.; Yum, S. I. Transdermal and Topical Drug Delivery Systems , Interpharm Press, Inc. p. 249-297, hereby expressly incorporated herein by reference). These patches are well known in the art and available commercially.
[0074] In general, the active ingredient (e.g., NMDA antagonist, optionally combined with anticonvulsants or other compounds which may reduce the side effects of NMDA antagonists, analgesics, and the like) of the invention will comprise from about 0.5 percent to about 40 percent by weight of the patch, preferably from about 10 percent to about 30 percent, more preferably from about 15 percent to about 25 percent, and most preferably from about 18 percent to about 22 percent by weight of the patch.
[0075] With gels, creams, or ointments, typically 1 to 10 applications are required per day. Generally, about 0.1 g/ cm2 of skin area to about 5 g/ cm2, preferably 1 g/ cm2 to about 2 g/ cm2 of a composition of the invention is administered to and around the application site.
[0076] When a patch is used to administer a composition of the invention, the dosage to achieve pain relief is determined by the active surface area of the medicated portion of the patch in direct contact with the skin. Several dosage strengths are advantageous depending upon the severity of the wound. In general, a physician can begin dosing with a low or intermediate strength patch and then, depending upon the effectiveness, adjust the dosage up or down by prescribing a patch of higher or lower active concentration or a patch of larger or smaller surface area, or, in some cases, multiple patches. In general, the composition of the invention will comprise from about 0.5 percent to about 20 percent by weight of the patch, preferably from about 5 percent to about 25 percent by weight of the patch. For matrix (drug-in-adhesive) type patches, the compositions of the invention will comprise from about 0.5 percent to about 20 percent by weight of the patch. For patches comprising a hydrogel, the compositions of the invention will comprise from about 0.5 percent to about 10 percent by weight of the patch. Fresh patches may be administered multiple times per day, but, preferably, a fresh patch is administered about every 18 to about every 48 hours, more preferably daily.
EXAMPLES
[0077] All chemicals used in the following examples are available from commercial sources in the United States of America for instance, Hawkins Pharmaceuticals (Minneapolis, MN) or B&B Pharmaceuticals (Aurora, CO). The preferred transdermal base "Lipoderm" is only available from the Professional Compounding Centers of America (PCCA). However, other transdermal bases are available from Hawkins Pharmaceuticals (e.g., "Lipo Cream") or from Medisca, Inc. (Plattsburg, NY). "Krisgel" (a thickener) is available only from PCCA, but similar commercial products are available from other chemical suppliers, e.g., "Tommy Gel" from Hawkins Pharmaceuticals. All reagents used in the Examples below are also commercially available from international standard sources, for example from, Spectrum Laboratory Products, Inc. Gardena, Calif.; Lab Express International Inc. NJ; AK Chemical Tech and Shandong Zhonggong Chemical Co.Ltd., Shanghai Gupeng International Trading Co., Ltd., Beijing Medicine Chemical Co., Ltd., in China; Greenspharma, Maps Pharmaceuticals of India. Additional searches online will result in additional sources for such compounds. One source for gabapentin is Spectrum Laboratory Products, Inc. and ketamine hydrochloride is from Medisca, Inc., Plattsburg, N.Y.
[0078] Transdermal bases differ from topical bases, e.g., petrolatum or cold cream, in that they facilitate the penetration of the active chemicals through all dermal layers. This subcutaneous entry, in turn, allows the active chemicals to penetrate the nerve fibers themselves. The PCCA transdermal base Lipoderm is preferred due to its proven penetration superiority over PLO (pluronic-lecithin-organogel). Formulation [0079] Ketamine HCl and Gabapentin powders can be accurately weighed by any FDA-approved scale. Water is measured using any approved cylindrical graduate. The powders are first filtered through a fine-mesh screen into a glass mortar then dissolved by the addition of water. An electronic mortar and pestle (EMP) is equally suitable in place of a manual glass mortar and pestle. The Lipoderm (or similar) transdermal base is then geometrically levigated into the dissolved powders. Krisgel (or similar) is then stirred into the mixture until evenly distributed. The mixture is then milled in a three-roller ointment mill (Exakt 50 or similar) and then dispensed in an appropriate ointment jar. Gabapentin can also be in weights of 3%.
[0080] Gabapentin can also be in weights of 3% with an increase in the amount of the Lipoderm Base.
[0081] The anticipated dose of Neurocreme is up to 2-5 grams per day. This dose translates to a topical administration of 400 mg of ketamine hydrochloride and 60 mg of gabapentine.
[0082] In one example, the active ingredients of the compositions described herein are composed of two chemicals within a transdermal base. The chemicals are (1) ketamine hydrochloride, an N-methyl-D-aspartate (NMDA) calcium channel antagonist in concentrations of 15% or 20% when combined with gabapentin. (2) Gabapentin, a glutamate antagonist at the NMDA and AMPA (sodium channel) receptor sites. Its concentration is typically 3%, but can be increased to 6% or decreased for gabapentin-sensitive patients. The transdermal vehicle Lipoderm® is used. This vehicle is a gel, but has the appearance and feel of a cream. It has the exceptional ability to contain up to 50% of its weight in active drugs. It is also cosmetically elegant and has a hypoallergenic compatibility with human dermis. The combination of the 2 agents within the Lipoderm® base act synergistically to relieve neuropathic pain.
[0083] One method of preparation is as follows. Ketamine and gabapentin powders were filtered through a fine-mesh screen into the appropriate vessel (e.g., a glass mortar.) Powders were wetted with sufficient propylene glycol. Some Lipoderm® was added to suspend the wet powders. The remainder of Lipoderm® was added and triturated till mixed. Krisgel® 1% (of the total compound) was added to thicken. An ointment mill was used to completely mix and smooth the cream. The resulting cream looks and feels like custard.
[0084] Aqueous-Phase Solution: Sorbitol solution, water, and PEG-100 stearate, were added to a Groen kettle (Model "TDB/8-20 CFC", Groen Division, Dover Corporation, Elk Grove Village, 111.). The kettle has a self-contained water jacket. The temperature was maintained within the range of about 70° C. to about 80° C. The kettle was covered, and the mixture was heated and stirred. When a solution resulted, the methylparaben, ketamine hydrochloride, and gabapentin were added. Stirring and heating continued until all ingredients were dissolved.
[0085] Oil-Phase Solution: Cetyl alcohol, isopropyl myristate, glycerol stearate and petrolatum were added to a stainless-steel container immersed in a hot water bath. The water-bath temperature was maintained in the range of 70° C. to 80° C. using a hot-plate. The solution was heated and stirred (Lab-Stirrer, Model LR 400 C, Fisher Scientific Inc., Pittsburgh, Pa.) until a homogenous liquid resulted. Propylparaben was then added and stirring and heating continued until the propylparaben was completely dissolved.
[0086] The oil phase (70° C.) was slowly poured into the aqueous phase (70° C.) and the resulting mixture stirred for 10 minutes using the kettle-stirring device. The kettle stirring device was then disassembled and the mixture emulsified using a high-shear homogenizer (PowerGen Homogenizer, Model 700D, Fisher Scientific Inc., Pittsburgh, Pa.) for 15 minutes. The kettle stirring device was reassembled to stir the resulting emulsion while the hot water in the kettle jacket was replaced with ice water to cool the emulsion. After the emulsion temperature dropped below 40° C, simethicone was added and the emulsion was then mixed for another 15 minutes using the kettle-stirring device. A Grisona MA filling machine (NAG Nahma AG, Unterageri, Austria) was used to fill the emulsion into 60 gram aluminum tubes (Peerless Tube Company, Bloomfield, N.J.).
[0087] The oil-phase-droplet diameters (weight mean diameter) were measured via laser-light diffraction (Malvern Mastersizer S Laser Diffractor, Malvern Instruments Ltd, Malvem, UK). Prior to the analysis, emulsion samples were dispersed in a 6.5% solution of PEG-100 stearate in purified water. Sample refractive index and carrier-fluid refractive index were set at 1.5295 and 1.33, respectively. The default setting for the Presentation and Analysis Model is "OHD" and "Polydisperse".
[0088] Gabapentin and ketamine hydrochloride were dissolved in the water in a glass beaker. Methylparaben and propylparaben were mixed with Transcutol-P in a separate beaker. The Transcutol-P solution containing the methylparaben and propylparaben was poured into the gabapentin/ketamine hydrochloride solution. A glass beaker containing the above solution was then placed inside a ice bath to cool the solution to approximately 5° C. Pluronic F 127 was added to the solution with continuous mixing (Lab-Stirrer, Model LR 400 C, Fisher Scientific Inc., Pittsburgh, Pa.) for approximately 12 hours until a clear solution resulted. While maintaining the temperature just below about 10° C, the clear solution was filled into aluminum tubes. When the solution temperature equilibrated to room temperature, it transformed into a clear gel.
[0089] The three examples listed below are compositions according to the invention previously noted. They are all combinations of Ketamine HCl and Gabapentin. They all share the trademarked name "Neurocreme".
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000032_0002
Example 4 - Neurocreme 30% - 1 OQg example size
Figure imgf000032_0003
Administration
[0090] The compositions described herein are applied two ways via massage: (1) directly to the pain site or appropriate ganglion and (2) into the appropriate dermatome on the spine.
[0091] Plan 1 was normally used first, especially if the pain locus is below the patient's waist line (due to reduced systemic circulation of the agents.) The patient is instructed to find the most precise area of pain — if possible — by using a blunt, pointed object (i.e., fingertip, pen tip, etc.) By use of a "checkerboard pattern" search, many times the pain locus is discovered. For example, a foot pain locus may be found by pressing a fingertip on one side of the ankle for approximately 2 seconds then moving the fingertip an inch towards the other side of the ankle. This pressure is repeated "checkerboard style"(across and downward) until the entire foot — top and bottom — has been covered. The patient takes note of what area(s) hurt most and then treats the area(s) with Vz gram or 1 gram of cream at each pain site. If a precise locus cannot be found, then a 1 gram dose to the ganglion located 3A inch below and 3A inch behind the inside anklebone will suffice. This ganglion is responsible for innervation of the foot via the L-4, L-5, S-I , and S-2 dermatomes. Other ganglia may be used similarly for pain loci at other anatomical sites. An anesthesiologist — or a medical professional with a thorough understanding of human anatomy — should be consulted for the most appropriate ganglion (or ganglia) to be used.
[0092] Plan 2 was used when there is insufficient analgesia provided by Plan 1. Plan 2 requires massage of the cream into the appropriate dermatome on the spinal column. The patient is shown where the correct dermatome application site (on the spine) is for the painful area described by the patient. For example, a foot pain locus requires cream application to the L-4, L-5, S-I, and S-2 vertebrae on the spine.
[0093] How much cream to apply depends on (1) the pain site and (2) pain severity. The patient is instructed to use Plan 1 first. During the counseling session, the patient learns to (1) find the pain using the "checkerboard technique" described above and (2) prepare the skin for application by warming the site with a very warm, slightly moist cloth. A minimum dose — usually between V2 to 1 gram — is suggested as a starting dose. A (l-gram+'Λ gram) dosing spoon is given to the patient for accurate measure. The patient is instructed to use this starting dose 3 times daily for 3 days unless side effects appear. If that happens, the patient is counseled to immediately cease the applications and call his/her doctor. After the 3 day period — and if no sign of analgesia nor side effects — the dose may be increased by Vz gram increments daily. For example, if a 1-gram dose to the site did not relieve the pain during the first 3 days, then the dose would be increased by V2 gram per application on day 4. If the pain was still not managed, the dose would be increased by another Vz gram dose on day 5. The dose total at that point would be 2 grams per application. This sequence would be repeated until (1) the pain is managed or (2) side effects begin. Note: Side effects at any time are the limiting factor for dosing. [0094] If Plan 1 does not provide sufficient analgesia within 7 days of the first application, then the patient is instructed to initiate Plan 2. Application to this area is explained above. Because the area is above the belt line, the patient is told that there is an increased risk of side effects. A 1 -gram dose at the correct dermatome is started with the proviso that the dose may be adjusted down or up after a 3 day dosing period. This is similar to Plan 1.
[0095] Dosing frequency is dependent on the cream's duration of action. Duration of action varies from patient to patient. Normally, the cream is applied 3 times daily, but more frequent — or less frequent — applications are possible. Again, the limiting factor is side effects. Hence, if no side effects, then multiple daily applications are OK. The cream is a pain management "tool". As such, the cream may be used as often as necessary (subject to side effects.)
Objectives and Advantages
[0096] Pain management is one objective of the compositions and methods described herein. The methods and compositions described herein can ameliorate neuropathic pain in patients. The compositions and methods described herein have the following advantages: (1) Surveys have shown that >75% of patients using the compositions described herein have managed their neuropathic pain with at least one embodiment described herein; (2) the compositions described herein are effective against a wide variety of sympathetically mediated pain (SMP) sources — including various neuropathies, low back pain, sciatica, and post-spinal surgery pain; (3) the doses needed to control neuropathic pain are relatively small (see survey, Table 1); (4) dose volumes are also small — a distinct application advantage; (5) patients affected by side effects total less than 22% (includes those who "failed" the cream); (6) the compositions described herein are cosmetically elegant; (7) the compositions described herein are easy to apply because they are readily absorbed by the prepared skin. TABLE 1
Number Compound Initial Pain Amount Application Pain Level: Duration of of Components Level (10- Applied Frequency One Week Action Patients point scale) (Times/day)
1 Neurocreme 10% 1.5 grams 2.8 7 4 hours
20 Neurocreme 15% 7.2 1.6 grams 2.8 3.75 3.8 22 Neurocreme 20% 7.9 1.4 grams 4.5 3.35 4.9
1 Neurocreme 25% 10 3 grams 2 2 X
[0097] Table 1 above describes the most commonly used varieties of the compositions described herein. A subjective 10-point pain scale was used by the patients at baseline and at 7 days to describe their pain. A "1 " essentially meant no pain. A "10" described very severe pain — the kind that leaves one in agony. The amount applied was judged by the number of 1 gram — /4 gram dispensing spoons used per application. There was tremendous Application Frequency variability. Application times ranged from once a day, every other day to 2, 3, 4, 5 and 6 times daily, or as needed.
[0098] Onset of analgesia for all four composition varieties share the same time period. These times varied from a half hour to over 72 hours. The onset times may differ from patient to patient.
[0099] Compound #1 (Example 1) achieved a pain reduction of 3.2 points=44% pain reduction. In the survey, 20 people used the 15% strength PLO-based (pluronic-lecithin organogel) transdermal gel but 3 reported treatment failure. This represents a success rate of 84%. 19 patients who used this formulation represent a statistically small sample. This compound was applied to patients with degenerative disc disease, diabetic peripheral neuropathy, fibromyalgia, lower pack pain, myelitis - legs/feet, P/S neuropathy and postherpetic neuralgia.
[0100] Compound #2 (Example 2) achieved a pain reduction of 3.4 points=a 43% pain reduction. More people (#22) have used the 20% strength of the compositions described herein than any other formulation. There were 5 reported failures. This compound was applied to patients with sciatica, spinal stenosis, rheumatoid arthritis, post amputation, polyneuropathy, occipital neuropathy in the legs/feet and the hands, and post-herpetic neuralgia.
[0101] Compound #3 (Example 3) achieved a pain reduction of 8 points with one patient, and thus=a 80% pain reduction for a patient with diabetic neuropathy.
[0102] The 10% ketamine compound was applied to a patient with lower back pain with minor reduction in pain.
[0103] The small sample size is representative but not indicative of the results of other patients. It is likely but not necessarily that greater amount of the NMDA antagonist may increase the amount of pain reduction and/or decrease the reported failures (e.g., via non-analgesia, or side effects).
Pain Reduction
[0104] A survey was provided to over 800 patients provided with various ketamine topical formulations combined with other compounds, using PLO or Lipoderm as the transdermal base. For all diagnoses, greater analgesia was achieved with ketamine concentrations greater than or equal to 15%, with best results from 20% or greater. Results show that the various topical formulations were efficacious in relieving pain in 643 of 824 diagnoses (78%). Most initial treatment failures were shown to be due to insufficient analgesia or side effects. The patients were treated for diabetic peripheral neuropathy, low back pain, polyneuropathy in the hands and feet, post-herpetic neuralgia, sciatica, CRPS/RSD, post-surgical neuropathy, and miscellaneous neuropathies including fibromyalgia.
[0105] All cited references including publications and patent documents cited in this specification are herein incorporated by reference in their entireties as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing methods and compositions have been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of these methods and compositions that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. The present invention is not to be limited in scope by the specific embodiments disclosed in the examples, which are intended as illustrations of a few aspects of the invention, and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A topical composition for the treatment of peripheral neuropathy comprising a therapeutically effective amount of at least one NMDA antagonist and only one additional active compound, wherein the composition is formulated in a pharmaceutically acceptable carrier for topical administration.
2. A topical composition for the treatment of peripheral neuropathy consisting essentially of a therapeutically effective amount of at least one NMDA antagonist and an anticonvulsant in a pharmaceutically acceptable carrier for topical administration.
3. The topical composition of claims 1 and 2, wherein said NMDA antagonist is ketamine or norketamine.
4. The topical composition of claims 2, wherein said anticonvulsant is gabapentin or pregablin.
5. The topical composition of claims 1 and 2, wherein said topical composition comprises 15% or greater of the NMDA antagonist.
6. The topical composition of claims 1 and 2, wherein said topical composition comprises 20% or greater of the NMDA antagonist.
7. The topical composition of claims 1 and 2, wherein said topical composition comprises 25% or greater of the NMDA antagonist.
8. The topical composition of claims 1 and 2, wherein said NMDA antagonist is ketamine.
9. The topical composition of claims 1 and 2, wherein said topical composition comprises less than 10% gabapentin.
10. The topical composition of claims 1 and 2, wherein said topical composition comprises about 20% ketamine and about 3% gabapentin.
1 1. The topical composition of claims 1 and 2, wherein said topical composition comprises about 15% ketamine and about 3% gabapentin.
12. The topical composition of claims 1 and 2, wherein said topical composition comprises more than one NMDA antagonist.
13. A method for treating a subject suffering from peripheral neuropathy, said method comprising topically administering an effective amount of a topical composition of Claims 1 and 2.
14. The method of claim 13, wherein the peripheral neuropathy is diabetic neuropathy.
15. The method of claim 13, wherein the peripheral neuropathy was induced by a toxic agent.
16. The method of claim 15, wherein said toxic agent is a chemotherapeutic agent.
17. The method of claim 13, wherein said peripheral neuropathy is cancer induced peripheral neuropathy.
18. The method of claim 13, wherein the peripheral neuropathy manifests as a post-surgical complication.
19. The method of claim 13, wherein the peripheral neuropathy is lower back pain.
20. The method of claim 13, wherein the peripheral neuropathy is chronic.
PCT/US2009/058446 2008-09-27 2009-09-25 Topical formulations for treatment of neuropathy WO2010036937A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US13/120,894 US8629184B2 (en) 2008-09-27 2009-09-25 Topical formulations for treatment of neuropathy
AU2009296457A AU2009296457A1 (en) 2008-09-27 2009-09-25 Topical formulations for treatment of neuropathy
CA2738468A CA2738468A1 (en) 2008-09-27 2009-09-25 Topical formulations for treatment of neuropathy
CN2009801471678A CN102223791A (en) 2008-09-27 2009-09-25 Topical formulations for treatment of neuropathy
EP09816933A EP2334176A4 (en) 2008-09-27 2009-09-25 Topical formulations for treatment of neuropathy
US14/155,231 US20140194514A1 (en) 2008-09-27 2014-01-14 Topical formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10071108P 2008-09-27 2008-09-27
US61/100,711 2008-09-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/120,894 A-371-Of-International US8629184B2 (en) 2008-09-27 2009-09-25 Topical formulations for treatment of neuropathy
US14/155,231 Continuation US20140194514A1 (en) 2008-09-27 2014-01-14 Topical formulations

Publications (1)

Publication Number Publication Date
WO2010036937A1 true WO2010036937A1 (en) 2010-04-01

Family

ID=42060106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058446 WO2010036937A1 (en) 2008-09-27 2009-09-25 Topical formulations for treatment of neuropathy

Country Status (6)

Country Link
US (2) US8629184B2 (en)
EP (1) EP2334176A4 (en)
CN (1) CN102223791A (en)
AU (1) AU2009296457A1 (en)
CA (1) CA2738468A1 (en)
WO (1) WO2010036937A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130210867A1 (en) * 2010-04-15 2013-08-15 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
WO2014168228A1 (en) * 2013-04-12 2014-10-16 マルホ株式会社 Composition for topical use
JP2016166231A (en) * 2013-01-18 2016-09-15 有限会社ケムフィズ Medicines for treatment of neuropathic diseases
US9469601B2 (en) 2012-12-04 2016-10-18 Pierre Fabre Medicament Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
WO2018106108A1 (en) 2016-12-06 2018-06-14 KEPPEL HESSELING, Jan Marius Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
US10195180B2 (en) 2011-10-05 2019-02-05 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
US11285099B2 (en) 2016-12-06 2022-03-29 Topical Innovations B.V. Topical phenytoin for use in the treatment of peripheral neuropathic pain

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076339A1 (en) * 2011-11-22 2013-05-30 Servicio Andaluz De Salud Combined preparations and compositions for the treatment of fibromyalgia
US9592241B2 (en) 2011-12-27 2017-03-14 Cmpd Licensing, Llc Silicone-based composition for skin treatment
WO2013115759A1 (en) * 2012-02-01 2013-08-08 Horvat Branimir L Topical medications for controlling epidermal symptoms
US11207316B2 (en) * 2014-05-30 2021-12-28 West Virginia University Ketamine or dextromethorphan formulations and methods of use
WO2016061328A1 (en) * 2014-10-15 2016-04-21 Maruho Co., Ltd. Topical composition
CN107530318A (en) 2015-03-02 2018-01-02 阿福金制药有限责任公司 Sex therapy is influenceed with the regional area nerve of cannboid
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20180161388A1 (en) * 2015-05-18 2018-06-14 Beth Israel Deaconess Medical Center, Inc. Substance p, mast cell degranulation inhibitors, and peripheral neuropathy
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC Ketamine transdermal delivery system
WO2017173442A1 (en) * 2016-04-01 2017-10-05 Good Pharmaceutical Development Company, Llc Topical compositions for neuropathic pain
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
AU2017341927B2 (en) * 2016-10-14 2021-12-16 CNS Biosciences, Inc. Treating neuropathic pain in spinal cord injured individuals
US20220054412A1 (en) * 2020-08-20 2022-02-24 Jason Pool Topical formulation and methods for neuropathy relief

Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755535A (en) 1986-04-23 1988-07-05 Nelson Research & Development Co. Compositions comprising 1-substituted azacycloalkenes
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4808414A (en) 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US4920101A (en) 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5034400A (en) 1989-10-20 1991-07-23 Olney John W Method for preventing neurotoxic side effects of NMDA antagonists
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5474990A (en) 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
WO1998007447A1 (en) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5767130A (en) 1989-10-20 1998-06-16 Olney; John W. Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists
WO1999012537A1 (en) 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US5985586A (en) 1993-04-20 1999-11-16 Sibia Neurosciences, Inc. Methods for identifying compounds that modulate the activity of human N-methyl-D-aspartate receptors
US6025369A (en) 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
WO2000053225A1 (en) 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6251948B1 (en) 1990-03-02 2001-06-26 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
WO2001089448A2 (en) 2000-03-28 2001-11-29 Olney John W Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects
WO2002000434A1 (en) 2000-06-28 2002-01-03 Fujimori Kogyo Co., Ltd. Plastic film for medical liquid container
US20020016319A1 (en) 1998-02-25 2002-02-07 Olney John W. Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects
US6387957B1 (en) 1995-09-22 2002-05-14 Bruce M. Frome Preparation of topical regional compositions for the relief of pain
US20020068754A1 (en) 1998-02-25 2002-06-06 Olney John W. Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects
US20020177592A1 (en) 1998-02-25 2002-11-28 Olney John W. Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects
WO2003061656A1 (en) 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003091241A1 (en) 2002-04-26 2003-11-06 Pfizer Japan Inc. 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
US20040076648A1 (en) 2001-08-17 2004-04-22 Epicept Corporation Topical compositions and methods for treating pain
US20040101582A1 (en) 2002-11-25 2004-05-27 Richard Wolicki Treatment of neuropathy
WO2004045601A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040204366A1 (en) 2001-04-27 2004-10-14 Gavril Pasternak Topical anesthetic/opioid formulation and uses thereof
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
US20070225257A1 (en) * 2003-04-09 2007-09-27 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] Phosphonic Acid and Methods of Use Thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225257A (en) * 1880-03-09 williams
US28789A (en) * 1860-06-19 Boiler foe
US184817A (en) * 1876-11-28 Improvement in pavements
US6166085A (en) 1995-04-14 2000-12-26 The Regents Of The University Of California Method of producing analgesia
AU3990895A (en) 1995-12-05 1997-06-27 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US5801188A (en) 1997-01-08 1998-09-01 Medtronic Inc. Clonidine therapy enhancement
WO1999038574A1 (en) * 1998-02-02 1999-08-05 Cook Arnold J Jump rope
GB9902651D0 (en) 1999-02-05 1999-03-31 Bioglan Lab Ltd Pharmaceutical compositions
US6376530B1 (en) 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
BR0012058A (en) 1999-07-02 2002-05-14 Warner Lambert Co Synergistic combination: gabapentin and pregabalin
US6147102A (en) 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US6689399B1 (en) 2000-03-16 2004-02-10 James R. Dickson Transdermal delivery of an anti-inflammatory composition
CA2315815A1 (en) 2000-07-19 2002-01-19 Peter R. Ford Topical pain relief composition and carrier
BR0208922A (en) 2001-04-19 2004-04-20 Warner Lambert Co Fused Bicyclic or Tricyclic Amino Acids
AR036873A1 (en) 2001-09-07 2004-10-13 Euro Celtique Sa PIRIDINAS ARIL REPLACED A, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT
US6730667B2 (en) 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
US20030100931A1 (en) 2001-11-28 2003-05-29 Keith Mullett Brain signal feedback for pain management
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755535A (en) 1986-04-23 1988-07-05 Nelson Research & Development Co. Compositions comprising 1-substituted azacycloalkenes
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4808414A (en) 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US4920101A (en) 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US5616580A (en) 1989-10-20 1997-04-01 Olney; John W. Pharmacological composition for preventing neurotoxic side effects of NMDA antagonists
US5474990A (en) 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
US5767130A (en) 1989-10-20 1998-06-16 Olney; John W. Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists
US5034400A (en) 1989-10-20 1991-07-23 Olney John W Method for preventing neurotoxic side effects of NMDA antagonists
US6251948B1 (en) 1990-03-02 2001-06-26 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5985586A (en) 1993-04-20 1999-11-16 Sibia Neurosciences, Inc. Methods for identifying compounds that modulate the activity of human N-methyl-D-aspartate receptors
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6387957B1 (en) 1995-09-22 2002-05-14 Bruce M. Frome Preparation of topical regional compositions for the relief of pain
US6025369A (en) 1996-05-03 2000-02-15 The Board Of Regents Of The University Nebraska N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis
WO1998007447A1 (en) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO1999012537A1 (en) 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US20020177592A1 (en) 1998-02-25 2002-11-28 Olney John W. Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects
US20020068754A1 (en) 1998-02-25 2002-06-06 Olney John W. Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects
US20020016319A1 (en) 1998-02-25 2002-02-07 Olney John W. Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects
WO2000053225A1 (en) 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO2001089448A2 (en) 2000-03-28 2001-11-29 Olney John W Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects
WO2002000434A1 (en) 2000-06-28 2002-01-03 Fujimori Kogyo Co., Ltd. Plastic film for medical liquid container
US20040204366A1 (en) 2001-04-27 2004-10-14 Gavril Pasternak Topical anesthetic/opioid formulation and uses thereof
US20040076648A1 (en) 2001-08-17 2004-04-22 Epicept Corporation Topical compositions and methods for treating pain
WO2003061656A1 (en) 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003091241A1 (en) 2002-04-26 2003-11-06 Pfizer Japan Inc. 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
WO2004045601A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040101582A1 (en) 2002-11-25 2004-05-27 Richard Wolicki Treatment of neuropathy
US20070225257A1 (en) * 2003-04-09 2007-09-27 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] Phosphonic Acid and Methods of Use Thereof
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
"Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy", September 2005, UNIVERSITY HEALTH NETWORK
"Percutaneous Penetration Enhancers", 1995
"Remington: The Science and Practice of Pharmacy", vol. 1, 1995, pages: 390 - 391
"Remington: The Science and Practice of Pharmacy", vol. 2, 1995, pages: 1463 - 1486
"Remington: The Science and Practice of Pharmacy", vol. 2, 1995, pages: 1509 - 1515
AARTS, MM, TYMIANSKI M: "Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors", BIOCHEMICAL PHARMACOLOGY, vol. 66, no. 6, 2003, pages 877 - 886
ABIZAID A, LIU Z, ANDREWS Z, SHANABROUGH M, BOROK E, ELSWORTH J, ROTH R, SLEEMAN M, PICCIOTTO M, TSCHOP M: "Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite", J CLIN INVEST, vol. 116, no. 12, 2006, pages 3229 - 39
ALBERS ET AL., CLINICAL NEUROPHARM., vol. 15, 1992, pages 509
ALLEN, TERENCE: "Particle Size Measurement", vol. 483, 1990
BAKONJA M, BAYDOUN A, EDWARDS K R ET AL.: "Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus-a randomized controlled trial", JAMA, vol. 280, 1998, pages 1831 - 1836
BERNARD IDSON ET AL.: "Pharmaceutical Emulsions in 1 Pharmaceutical Dosage Forms: Disperse Systems", vol. 199, 1988
BIGGE, BIOCHEM. PHARMACOL., vol. 45, 1993, pages 1547
BROUN ET AL., AM. J. CLIN. ONCOL., vol. 16, 1993, pages 18 - 21
CASEY ET AL., BRAIN, vol. 96, 1973, pages 69 - 86
CHAWLA, PS, KOCHAR MS: "What's new in clinical pharmacology and therapeutics", WMJ, vol. 105, no. 3, 2006, pages 24 - 29
CROWLEY ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICAL COMPOUNDING, vol. 2, 1998, pages 122 - 1273
EBLEN F, LOSCHMANN P, WULLNER U, TURSKI L, KLOCKGETHER T: "Effects of 7-nitroindazole, NG- nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate- induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions", EUR J PHARMACOL, vol. 299, no. 1-3, 1996, pages 9 - 16
ELLISON G.: "The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Research", BRAIN RESEARCH REVIEWS, vol. 20, no. 2, 1995, pages 250 - 267
FADEN ET AL., TRENDS PHARMACOL. SCI., vol. 13, 1992, pages 29
FARBER N, HANSLICK J, KIRBY C, MCWILLIAMS L, OLNEY J: "Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity", NEUROPSYCHOPHARMACOLOGY, vol. 18, no. 1, 1998, pages 57 - 62
FARBER NB, HEINKEL C, DRIBBEN WH, NEMMERS B, JIANG X.: "In the adult CNS, ethanol prevents rather than produces NMDA antagonist-induced neurotoxicity", BRAIN RES, vol. 1028, no. 1, 2004, pages 66 - 74
FARBER, N B ET AL.: "Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity", MOL PSYCHIATRY, vol. 7, no. 7, 2002, pages 726 - 733
FIX AS, HORN JW, WIGHTMAN KA ET AL.: "Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex", EXP. NEUROL., vol. 123, no. 2, 1993, pages 204 - 15
FRANKIEWICZ T, PILC A, PARSONS C: "Differential effects of NMDA-receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices", NEUROPHARMACOLOGY, vol. 39, no. 4, 2000, pages 631 - 42
GENNARO, A. R.: "Remington: The Science and Practice of Pharmacy", 2006, LIPPINCOTT, WILLIAMS & WILKINS
GHOSH, T. K. ET AL., PHARM. TECH., vol. 17, 1993, pages 62
GHOSH, T. K. ET AL., PHARM. TECH., vol. 17, 1993, pages 72
GHOSH, T. K., PFISTER, W. R., YUM, S. 1.: "Transdermal and Topical Drug Delivery Systems", INTERPHARM PRESS, INC., pages: 249 - 297
GHOSH, T.K. ET AL., PHARM. TECH., vol. 17, 1993, pages 68
GRASSHOFF C, DREXLER B, RUDOLPH U, ANTKOWIAK B: "Anaesthetic drugs: linking molecular actions to clinical effects", CURR. PHARM. DES., vol. 12, no. 28, 2006, pages 3665 - 79
HARRISON N, SIMMONDS M: "Quantitative studies on some antagonists ofN- methyl D-aspartate in slices of rat cerebral cortex", BR J PHARMACOL, vol. 84, no. 2, 1985, pages 381 - 91
HARTLEY DM, MONYER H, COLAMARINO SA, CHOI DW: "7-Chlorokynurenate Blocks NMDA Receptor-Mediated Neurotoxicity in Murine Cortical Culture", EUR J NEUROSCI, vol. 2, no. 4, 1990, pages 291 - 295
HUGON J: "ALS therapy: targets for the future", NEUROLOGY, vol. 47, no. 6, 1996, pages 251 - 4
JACOBSON ET AL., J. PHARMACOL. EXP. THER., vol. 110, 1987, pages 243
JIA-HE LI ET AL., J. MED. CHEM., vol. 38, 1995, pages 1955
KHAN MJ, SEIDMAN MD, QUIRK WS, SHIVAPUJA BG: "Effects of kynurenic acid as a glutamate receptor antagonist in the guinea pig", EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN FEDERATION OF OTO-RHINO-LARYNGOLOGICAL SOCIETIES (EUFOS) : AFFILIATED WITH THE GERMAN SOCIETY FOR OTO-RHINO-LARYNGOLOGY - HEAD AND NECK SURGERY, vol. 257, no. 4, 2000, pages 177 - 81
KIM AH, KERCHNER GA, CHOI DW.: "CNS Neuroproteciton", 2002, SPRINGER, article "Blocking Excitotoxicity", pages: 3 - 36
KO JC, SMITH TA, KUO WC, NICKLIN CF: "Comparison of anesthetic and cardiorespiratory effects of diazepam-butorphanol-ketamine, acepromazine-butorphanol-ketamine, and xylazine-butorphanol-ketamine in ferrets", JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, vol. 34, no. 5, 1998, pages 407 - 16
KOLESNIKOV ET AL., LIFE SCI., vol. 55, 1994, pages 1393
KOLESNIKOV ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5162
KRISTENSEN, JD, SVENSSON B, GORDH T JR: "The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans", PAIN, vol. 51, no. 2, 1992, pages 249 - 253
MAAS, AL: "Neuroprotective agents in traumatic brain injury", EXPERT OPIN INVESTIG DRUGS., vol. 10, no. 4, 2001, pages 753 - 67
MACDONALD, NEUROLOGIC CLINICS, vol. 9, 1991, pages 955 - 967
MELDRUM ET AL., TRENDS PHARMACOL. SCI., vol. 11, 1990, pages 379
MUIR, KW, LEES KR: "Clinical experience with excitatory amino acid antagonist drugs", STROKE, vol. 26, no. 3, 1995, pages 503 - 513
MUIR, KW: "Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists", CURRENT OPINION IN PHARMACOLOGY, vol. 6, no. 1, 2005, pages 53 - 60
NADINE, BOUHASSIRA, ACTA. NEUROL. SCAND, no. 173, 1999, pages 12 - 24
OLNEY J, LABRUYERE J, WANG G, WOZNIAK D, PRICE M, SESMA M: "NMDA antagonist neurotoxicity: mechanism and prevention", SCIENCE, vol. 254, no. 5037, 1991, pages 1515 - 8
OLNEY J, LABRUYERRE J, PRICE MT.: "Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs", SCIENCE, vol. 244, no. 4910, 1989, pages 1360 - 1362
OXOLS, SEMINARS IN ONCOLOGY, vol. 16, no. 6, 1989, pages 22 - 30
POPIK P, LAYER RT, SKOLNICK P: "The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.", PSYCHOPHARMACOLOGY, vol. 114, no. 4, 1994, pages 672 - 4
ROCKSTROH, S, EMRE M, TARRAL A, POKORNY R: "Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans", PSYCHOPHARMACOLOGY, vol. 124, no. 3, 1996, pages 261 - 266
ROGAWSKI, TRENDS PHARMACOL. SCI., vol. 14, 1993, pages 325
ROWBATHAM M, HARDIN N, STACEY B ET AL.: "Gabapentin for the treatment of postherpetic neuralgia-a randomized controlled trial.", JAMA, vol. 280, 1998, pages 1837 - 1842
STEINBERG ET AL., NEUROSCI. LETT., vol. 133, 1991, pages 225
THURKAUFET, J. MED. CHEM., vol. 31, 1988, pages 2257
TRYBA M, GEHLING M.: "Clonidine--a potent analgesic adjuvant", CURR OPIN ANAESTHESIOL., vol. 15, no. 5, October 2002 (2002-10-01), pages 511 - 7
VAN DEN BOS R, CHARRIA ORTIZ G, COOLS A: "Injections of the NMDA-antagonist D-2-amino-7-phosphonoheptanoic acid (AP-7) into the nucleus accumbens of rats enhance switching between cue-directed behaviours in a swimming test procedure", BEHAV BRAIN RES, vol. 48, no. 2, 1992, pages 165 - 70
WILLETTS ET AL., TRENDS PHARMACOL. SCI., vol. 11, 1990, pages 423
WOLFE ET AL., AM. J EMERG. MED., vol. 13, 1995, pages 174
WONG BY, COULTER DA, CHOI DW, PRINCE DA: "Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices", NEUROSCI. LETT., vol. 85, no. 2, 1988, pages 261 - 6

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130210867A1 (en) * 2010-04-15 2013-08-15 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
US10195180B2 (en) 2011-10-05 2019-02-05 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
US9469601B2 (en) 2012-12-04 2016-10-18 Pierre Fabre Medicament Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
US9687459B2 (en) 2012-12-04 2017-06-27 Pierre Fabre Medicament Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
JP2016166231A (en) * 2013-01-18 2016-09-15 有限会社ケムフィズ Medicines for treatment of neuropathic diseases
US10004710B2 (en) 2013-01-18 2018-06-26 Kemphys Ltd. Medicament for therapeutic treatment of neuropathic disease
US10485776B2 (en) 2013-01-18 2019-11-26 Kemphys Ltd. Medicament for therapeutic treatment of neuropathic disease
WO2014168228A1 (en) * 2013-04-12 2014-10-16 マルホ株式会社 Composition for topical use
WO2018106108A1 (en) 2016-12-06 2018-06-14 KEPPEL HESSELING, Jan Marius Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
US11147799B2 (en) 2016-12-06 2021-10-19 Jan Marius Keppel Hesselink Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain
US11285099B2 (en) 2016-12-06 2022-03-29 Topical Innovations B.V. Topical phenytoin for use in the treatment of peripheral neuropathic pain

Also Published As

Publication number Publication date
CA2738468A1 (en) 2010-04-01
CN102223791A (en) 2011-10-19
EP2334176A1 (en) 2011-06-22
US8629184B2 (en) 2014-01-14
US20110178177A1 (en) 2011-07-21
EP2334176A4 (en) 2012-05-02
AU2009296457A1 (en) 2010-04-01
US20140194514A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
US8629184B2 (en) Topical formulations for treatment of neuropathy
US7687080B2 (en) Treatment of neuropathy
EP1248613B1 (en) Clonidine preparations
RU2754846C1 (en) Local anaesthetic compositions
US20130209585A1 (en) Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
CA2676991A1 (en) Methods and compositions for the treatment of pain
US11147799B2 (en) Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain
US10137079B2 (en) Transdermal composition for treating pain
WO2008001204A2 (en) Transdermal compositions of pramipexole having enhanced permeation properties
EP1318801B1 (en) Topical analgesic compositions containing aliphatic polyamines and methods of using same
KR100347883B1 (en) New pharmaceutical composition of gel preparation containing local anaesthetic agents
US11813237B2 (en) Creatine, its derivatives, compositions and methods of use thereof
US8779003B2 (en) Method and composition for prolonging analgesic effect of local anesthetic
CN117618406A (en) Local anesthetic preparation composition and preparation method thereof
JPH083073A (en) Percutaneous absorbefacient and external agent for skin
JPH083070A (en) Percutaneous absorbefacient and external agent for skin
US20130338098A1 (en) Topical Analgesic Compositions Containing Aliphatic Polyamines and Methods of Using Same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980147167.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09816933

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2738468

Country of ref document: CA

Ref document number: 13120894

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009816933

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009296457

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009296457

Country of ref document: AU

Date of ref document: 20090925

Kind code of ref document: A